The QualityStocks Daily Tuesday, August 8th, 2023

Today's Top 3 Investment Newsletters

BioMedWire(VVOS) $0.3999 +53.22%

Schaeffer's(TLRY) $3.0200 +36.04%

ChineseWire(FRES) $3.3000 +30.90%

The QualityStocks Daily Stock List

Tilray, Inc. (TLRY)

Schaeffer's, InvestorPlace, The Street, StocksEarning, MarketBeat, StockEarnings, MarketClub Analysis, Trades Of The Day, QualityStocks, Daily Trade Alert, StockMarketWatch, Kiplinger Today, StreetInsider, The Online Investor, Wealth Insider Alert, Market Intelligence Center Alert, BUYINS.NET, Investopedia, Zacks, CFN Media Group, CNBC Breaking News, The Street Report, Daily Profit, StreetAuthority Daily, Early Bird, INO Market Report, Inside Trading, The Rich Investor, Tip.us, Top Pros' Top Picks, InvestmentHouse, Trading For Keeps, Trading Concepts, FreeRealTime, Eagle Financial Publications, InvestorsObserver Team, Investors Alley, Investment House, Outsider Club, wyatt research newsletter, Wealth Daily, VectorVest, TheTradingReport, The Night Owl, StrategicTechInvestor, Money Morning, Rick Saddler, InvestorsUnderground, AllPennyStocks, MarketClub, Marketbeat.com, Louis Navellier, Jim Cramer, Jason Bond and Stock Up Featured reported earlier on Tilray, Inc. (TLRY), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Tilray, Inc. (NASDAQ: TLRY) is a pharmaceutical firm that is engaged in research, growing, production and distribution of cannabinoids, recreational and medical marijuana. The firm operates through its Hemp and Cannabis Segments.

The firm’s Hemp segment sales are made up of broad spectrum hemp extract that contains CBD, hemp food and hemp seed, which are sold directly to consumers, or to wholesalers and retailers, in unlicensed operations. On the other hand, its Cannabis segment sales are made up of medical, adult-use and huge sales of marijuana under regulated licenses, which are sold directly to patients as well as to governments, pharmacies, wholesalers and retailers. The firm also provides its products to researchers for commercial purposes, as well as for clinical research applications and compassionate access.

Tilray was founded on January 24 in 2018 and is based in Nanaimo, Canada. The firm operates in other countries apart from Canada, including the United Kingdom, Argentina, the U.S., Australia, Switzerland, Chile, South Africa, Portugal, Croatia, New Zealand, Cyprus, Ireland, the Czech Republic, Israel and Germany.

Tilray develops marijuana based medicines, drops, dried marijuana and marijuana extracts, as well as oil products. The firm sells these products through various brands under it, including Manitoba Harvest, Dubon and Canaca. The firm’s subsidiary - FHF Holdings Ltd, also markets, manufactures and distributes consumer products that are hemp-based. Apart from a partnership with AB InBev to develop marijuana-infused drinks, the company recently announced that it would be merging with Aphria Inc., another Canadian cannabis firm.

Many anticipate that this merger may broaden both companies’ hold on the cannabis market, as this merger may make them one of the largest firms globally. Their combined range, from Tilray’s Portugal facility to Aphria’s CC Pharma asset in Germany, may also provide both firms with a competitive edge in the budding marijuana market.

Tilray, Inc. (TLRY), closed Tuesday's trading session at $3.02, up 36.036%, on 125,769,690 volume. The average volume for the last 3 months is 324,823 and the stock's 52-week low/high is $1.50/$5.12.

Capricor Therapeutics (CAPR)

StockMarketWatch, MarketClub Analysis, MarketBeat, BUYINS.NET, TraderPower, QualityStocks, TradersPro, StreetInsider, Schaeffer's, Wall Street Resources, HotOTC, Jason Bond, Penny Pick Finders, Buzz Stocks, OTCtipReporter, Marketbeat.com, PennyStockProphet, PennyStockScholar, Profitable Trader Authority, smartOTC, StockOodles, Streetwise Reports, The Street, Wall Street Mover and PoliticsAndMyPortfolio reported earlier on Capricor Therapeutics (CAPR), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Capricor Therapeutics Inc. (NASDAQ: CAPR) (FRA: 4LN2) is a clinical stage biotechnology firm that is engaged in developing transformative exosome and cell-based therapies for preventing and treating various rare ailments, like duchenne muscular dystrophy.

The firm has its headquarters in Beverly Hills, California and was incorporated in 2005. It operates in the healthcare sector, under the biotech and pharma sub-industry and serves consumers in Canada and the U.S.

The company is well positioned at the forefront of one of the biggest segments of the healthcare sectors in the US- cardiovascular disease, given that it’s a developer of innovative treatments. It is party to a collaboration agreement with Lonza Houston Inc. which entails developing its cell therapy candidate dubbed CAP-1002, indicated for treating duchenne muscular dystrophy as well as other ailments.

The enterprise’s product pipeline is made up of a formulation currently in pre-clinical development dubbed CAP-2003, indicated for treating trauma-related conditions and injuries and an allogeneic cardiac-derive treatment dubbed CAP-1002, which is indicated for treating cardiac conditions like post myocardial infarction with cardiac dysfunction and heart failure and is also currently in phase 2 clinical trials testing its effectiveness in treating cytokine storms linked to the coronavirus. This formulation also concluded phase 2 clinical trials testing its effectiveness in treating late stage Duchenne muscular dystrophy. In addition to this, the company is involved in developing 2 vaccine candidates for the potential prevention of the coronavirus, which are currently in the preclinical stage.

The firm’s CAP-1002 has shown tremendous potential in the management of Duchenne muscular dystrophy, which occurs in 1 in every 3600 live male births and affects about 200,000 young men and boys across the globe. The treatment’s success would not only address patients’ needs for a disease that has no cure but also bring in significant investments into the firm, which would enhance growth.

Capricor Therapeutics (CAPR), closed Tuesday's trading session at $5.73, up 21.6561%, on 325,024 volume. The average volume for the last 3 months is 159,378 and the stock's 52-week low/high is $3.30/$6.58.

electroCore (ECOR)

MarketBeat, QualityStocks, BUYINS.NET, StreetInsider, TradersPro, StockMarketWatch, PoliticsAndMyPortfolio, PennyStockScholar, OTCtipReporter, Penny Pick Finders, Profitable Trader Authority, Trades Of The Day, StockOnion, MarketClub Analysis, TopPennyStockMovers, InvestorPlace, InsiderTrades, HotOTC, Channelchek, Buzz Stocks and PennyStockProphet reported earlier on electroCore (ECOR), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

electroCore, Inc. (NASDAQ: ECOR) (FRA: 43E) is a medical device firm that is focused on developing and commercializing various nVNS (non-invasive vagus nerve stimulation) therapies for treating various conditions in rheumatology, neurology, respiratory and psychiatry.

The firm has its headquarters in New Jersey and was incorporated in September 2005 by Thomas J. Errico, Peter S. Staats, Steven M. Mendez and Joseph P. Errico. It operates under the healthcare sector, in the biotech and pharma sub-industry and serves consumers across the globe.

The company centers mainly on headaches like cluster and migraine, in anxiety, depression, gastric motility disorders and epilepsy. It sells its products to patients via health care professionals in Canada, Australia, Italy, Germany, the U.S. and the United Kingdom

The enterprise develops a bioelectronics medical therapy platform which modulates neurotransmitters and immune function via its effects on both the central and peripheral nervous systems. It is involved in the development of a prescription-only nVNS therapy dubbed gammaCore indicated for the treatment of acute pain linked to episodic cluster headaches and migraines in adults. It also produces a reloadable and rechargeable handheld delivery system known as gammaCore Sapphire, which is prescribed on a monthly basis, for multi-year use.

The firm recently entered into an agreement with Kromax International Corp, for the distribution of its gammaCore Sapphire product. This agreement will allow the product to reach consumers in China and Taiwan, which will help extend the firm’s consumer reach and boost the company’s growth.

electroCore (ECOR), closed Tuesday's trading session at $6.04, up 20.5589%, on 160,225 volume. The average volume for the last 3 months is 8.511M and the stock's 52-week low/high is $2.925/$10.5045.

One Step Vending (KOSK)

NetworkNewsWire, QualityStocks, Small Cap Firm, Jet-Life Penny Stocks, MicroCapDaily, OTCMagic, Penny Picks, Damn Good Penny Picks, Shiznit Stocks, Penny Stock Titans, PREPUMP STOCKS, Penny Stock Newsletter, GrowthPennyStocks, Penny Stock General, Stock Commander, Value Penny Stocks, Profitable Trader Authority, Mega Penny Stock Pick, StockRockandRoll, Penny Stock Prodigy, ProTrader, PennyStockLocks.com, PennyStockScholar, OTCtipReporter, Elite Stock Alerts, Epic Stock Picks, StocksToBuyNow, DamnGoodPennyStock, Equity Observer, Fortune Stock Alerts, Winston Small Cap, Whisper from Wall Street, Journal Transcript, MegaPennyStocks, Penny Stock Mobsters, OnPoint Stock Alert, OTCStars.com, Otcstockexchange, SeriousTraders, Wolf of Penny Stocks, PennyPickAlerts and theOTC.today reported earlier on One Step Vending (KOSK), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

One Step Vending Corp (OTC: KOSK) is a holding firm that is involved in the development, manufacture and servicing of micro market kiosks for corporations and businesses to provide packaged snacks and beverages along with customer loyalty solutions in the United States.

The firm has its headquarters in Harrison, New York and was incorporated in 2004, on June 21st. Prior to its name change in March 2015, the firm was known as Rewards Nexus Inc. It operates as part of the medical distribution industry, under the healthcare sector. The firm primarily serves consumers in the United States.

The company is focused on the acquisitions and cooperative agreements with companies that have the ability of growth, resulting in acquiring market share. It supports subsidiaries with key financial, sales, marketing, and operational changes designed to accelerate growth and shareholder value.

The enterprise, through its subsidiary, Sofos CBD Inc., focuses on wholesale distribution and retail of CBD products forming strategic partnerships with suppliers and stores. It aims to sell retail CBD products through the use of vending machines, online and is currently developing an online platform that will be launched in the future. The products of third-party suppliers include edibles such as tinctures, capsules, oils, gummies, and other products. In addition to this, it offers Earn IQ, a marketing solution for small to medium sized businesses desiring to capitalize on brand recognition and strengthen brand loyalty.

The company remains committed to extending its consumer reach and creating significant value for its shareholders.

One Step Vending (KOSK), closed Tuesday's trading session at $0.0056, off by 12.5%, on 8,510,865 volume. The average volume for the last 3 months is 8,192 and the stock's 52-week low/high is $0.0018/$0.014.

Azitra (AZTR)

InsiderTrades reported earlier on Azitra (AZTR), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Azitra Inc. (NYSE American: AZTR) is a pre-clinical biopharmaceutical firm focused on the development of treatments for precision dermatology using engineered proteins and live biotherapeutic products for the treatment of skin illnesses.

The firm has its headquarters in Branford, Connecticut and was incorporated in 2014. It operates as part of the biotechnology industry, under the healthcare sector. The firm serves consumers across the globe.

The company has built a proprietary platform that includes a microbial library comprised of approximately 1,500 unique bacterial strains that can be screened for unique therapeutic characteristics. The platform is augmented by an artificial intelligence and machine learning technology that analyzes, predicts and helps screen the company's library of strains for drug-like molecules. The company's initial focus is on the development of genetically engineered strains of Staphylococcus epidermidis, or S. epidermidis, which the company considers to be an optimal therapeutic candidate species for engineering of dermatologic therapies.

The enterprise’s pipeline is comprised of ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor; ATR-01, an engineered recombinant human filaggrin protein for treating ichthyosis vulgaris, a skin disease; and ATR-12, a genetically modified strain of S. epidermidis for treating Netherton syndrome, a skin disease.

The firm recently added two members to its board of directors, a move that may help grow the company to support clinical trials as well as its partnership with Bayer. This will in turn help generate value for its shareholders.

Azitra (AZTR), closed Tuesday's trading session at $2.51, off by 5.6391%, on 8,192 volume. The average volume for the last 3 months is 389,855 and the stock's 52-week low/high is $2.28/$5.18.

Longfor Group (LNGPF)

We reported earlier on Longfor Group (LNGPF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Longfor Group Holdings Limited (OTC: LNGPF) (HKG: 0960) (FRA: RLF) is an investment holding firm that is focused on property development, investment and management businesses.

The firm has its headquarters in Beijing, China and was incorporated in 1993. Prior to its name change in June 2018, the firm was known as Longfor Properties Company Limited. It operates as part of the real estate-development industry, under the real estate sector. The firm serves consumers in the People’s Republic of China.

The company operates through three segments; the Property Development, Property Investment, and Property Management and Related Services segments. The property development segment is engaged in the development and sale of office buildings, commercial properties, residential properties and car parks in China. The property investment segment is engaged in the leasing of investment properties developed by the company to generate rental income and to gain from appreciation in the properties’ values. Its property portfolio mainly includes retail properties in China, such as Chongqing North Paradise Walk, Chengdu Three Thousand Mall and Beijing Changying Paradise Walk, among others. On the other hand, the property management and related services segment is mainly engaged in the provision of property management services in China. The property development segment generates a majority of the company’s revenue. The company operates businesses in Beijing, Chengdu, Chongqing, Dalian, Hangzhou and Shanghai, among others.

The enterprise remains committed to executing its strategy while providing more diversified services as it grows into a customer-centered space construction service enterprise. This may in turn encourage more investments into the enterprise.

Longfor Group (LNGPF), closed Tuesday's trading session at $2.54, even for the day. The average volume for the last 3 months is 8.211M and the stock's 52-week low/high is $1.551302/$3.72.

FibroGen (FGEN)

MarketBeat, Schaeffer's, The Street, BUYINS.NET, Marketbeat.com, MarketClub Analysis, INO.com Market Report, Kiplinger Today, Trades Of The Day, Daily Trade Alert, StreetInsider, Barchart, InvestorPlace, Zacks, TraderPower, StockMarketWatch, TradersPro, Market FN, InvestmentHouse, FreeRealTime, SmallCapNetwork and AllPennyStocks reported earlier on FibroGen (FGEN), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

FibroGen Inc. (NASDAQ: FGEN) (LON: 01L8) (BMV: FGEN) (FRA: 1FG) is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics for the treatment of serious unmet medical needs.

The firm has its headquarters in San Francisco, California and was incorporated in 1993, on September 29th by Thomas B. Neff. It operates as part of the biotechnology industry, under the healthcare sector. The firm serves consumers around the globe.

The company is party to collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. It generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of its revenue to date has been generated from its collaboration agreements. The company seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates.

The enterprise’s lead product candidates include Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in phase III clinical development for anemia related with myelodysplastic syndromes; and Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer and Duchenne muscular dystrophy.

The company remains committed to modifying and advancing its formulations to better meet patient needs following their latest trial results. The success and approval of its formulations may help bolster the company’s overall growth.

FibroGen (FGEN), closed Tuesday's trading session at $1.44, off by 18.6441%, on 8,297,694 volume. The average volume for the last 3 months is 33,425 and the stock's 52-week low/high is $1.41/$25.69.

Hemostemix (HMTXF)

InvestorIntel reported earlier on Hemostemix (HMTXF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Hemostemix Inc. (OTCQB: HMTXF) (CVE: HEM) (FRA: 2VF0) is a clinical stage biotechnology firm that is focused on the development, manufacture and commercialization of blood-derived stem cell therapies for medical conditions not adequately addressed by existing treatments.

The firm has its headquarters in Calgary, Canada and was incorporated in 2006 by Thomas A. Smeenk and Roger Bergersen. It operates as part of the biotechnology industry, under the healthcare sector. The firm serves consumers around the globe.

The company has developed, patented and is scaling a patient’s blood-based stem cell therapeutics platform that includes angiogenic cell precursors, neuronal cell precursor and cardiomyocyte cell precursors. Its technology includes methods for collecting the synergetic cell population and manufacturing (isolation, enrichment and differentiation) a personalized regenerative therapy that can be administered to a patient within seven days of the initial cell collection. The company's wholly owned subsidiaries include Kwalata Trading Limited and PreCerv Inc.

The enterprise develops cell therapy products from the patient's own blood, which is a non-invasive source of therapeutic cells. Its lead product is ACP-01, an autologous cell therapy, which is in phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia in Canada and the United States.

The firm remains focused on better meeting patient medical needs via its formulations, whose success and approval will, in turn, generate additional shareholder value and positively influence investments into the firm.

Hemostemix (HMTXF), closed Tuesday's trading session at $0.11, up 4.7619%, on 33,425 volume. The average volume for the last 3 months is 452,531 and the stock's 52-week low/high is $0.0746/$0.29.

ElectraMeccanica Vehicles Corp. Ltd. (SOLO)

Green Car Stocks, InvestorPlace, QualityStocks, StocksEarning, Kiplinger Today, Schaeffer's, MarketClub Analysis, StockMarketWatch, TradersPro, StockEarnings, BUYINS.NET, Trades Of The Day, MarketBeat, The Street, Daily Trade Alert, TopPennyStockMovers, The Online Investor, VectorVest, PoliticsAndMyPortfolio, Small Cap Firm, GreenCarStocks, SmallCapVoice, Eagle Financial Publications and Cabot Wealth reported earlier on ElectraMeccanica Vehicles Corp. Ltd. (SOLO), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

EV charging can be a wild west at the moment, especially if you aren’t adequately prepared. Although charging EVs during trips covering long distances can be hard, it’s not impossible. The first, and arguably most important rule to EV travel, is adequate preparation.

Proper planning is key to electric vehicle travel, especially over long distances. Unfortunately, the United States doesn’t have the kind of public charging infrastructure that would allow spontaneous travel. This means figuring out how long your EV range will last and planning your route to ensure there are enough charging stations along the way to keep you charged.

You can use your car’s route planner or app to figure out how long you can travel before you have to charge. Once you figure that out, you will want to download the app of the company running the charging stations and create an account.

Practice proper charging etiquette. Most EV drivers who have used public chargers can attest to how other drivers can make the experience unpleasant. Line cutting, stealing spots from drivers who were there before you, pulling up to spots adjacent to chargers, and “stealing” the charger from drivers parked in the right spot is not uncommon at public charging stations.

Take note of the other drivers already present at charging stations when you arrive to figure out who is waiting for the available charger. If you talk to the other drivers, you may be lucky enough to find one willing to let you take their spot.

Learn as much as you can about your car and EV chargers. Different charging stations will likely have several types of plugs and will charge customers varying rates. Make sure you know your vehicle’s optimal wattage to optimize the charging experience. Newer EVs can gain up to 80% of charge in half an hour on a 350kW charger while older models can only handle 50kW chargers and take longer to fill up.

Figure out how to park at the charging station to ensure easy access to the charger for you and other drivers as well. Furthermore, you should know how the charging stations at your route operate, including the payment mode they accept and their operation hours.

Don’t charge your EV to capacity. Fast chargers generally fill the battery to 80% at high speeds before throttling down the charging speed to avoid damaging the batteries. As such, it could take you a while to fill up the remaining 20%. Depending on your EV model, it can take you an additional 30–40 minutes to charge the EV to full capacity.

Get out of the car while it’s charging. Did you know that vehicle climate controls can consume up to 15% of your battery range. As much as you may want to avoid the summer heat in your air-conditioned car, doing so will extend the time it takes to charge your car and keep other drivers waiting for longer. Wait at a nearby restaurant or store and disconnect your EV from the charger once it reaches 80%.

As more companies such as ElectraMeccanica Vehicles Corp. Ltd. (NASDAQ: SOLO) bring more EV models onto the market, the need to implement the rules above will become even greater so that everyone who needs to charge while on the road can do so with the least degree of inconvenience.

ElectraMeccanica Vehicles Corp. Ltd. (SOLO), closed Tuesday's trading session at $0.7393, off by 0.363881%, on 461,074 volume. The average volume for the last 3 months is 143,802 and the stock's 52-week low/high is $0.44/$1.87.

Mushrooms Inc. (MSRM)

We reported earlier on Mushrooms Inc. (MSRM), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Mushrooms (OTC: MSRM), a trailblazer in sustainable textile innovation, is in the final stages of filing a full patent application for its groundbreaking mycelium thread technology. Filing for the patent is part of the company’s mission to revolutionize the textile industry and represents a significant stride toward a more sustainable and ecologically conscious future while also advancing science and technology. According to the company, the unique characteristics of the mycelium thread position it as a “transformative force” across diverse sectors, including applications in the medical, military, aerospace, lifestyle and environmental spaces. The announcement noted that when natural properties of mycelium are combined with ingenious elements, the textile exhibits inherent antimicrobial qualities and the ability for microbial detection. Leading the development of this technology is Dr. Hyder Ali Khoja, the senior lead scientist for the Myco Thread project. “This project showcases that holding to high environmental standards does not mean a sacrifice of technological advancements; in fact, it exemplifies the opposite. By working in partnership with nature, it gives back tenfold,” said Mushrooms CEO Kimberly Carlson in the press release. “Dr. Hyder Khoja's role as our senior lead scientist on this project has been indispensable in driving this innovation forward. His diverse accomplishments in science and collaborative dedication have combined to pave the way for the mycelium thread's transformative impact.”

To view the full press release, visit https://ibn.fm/qlvo3

About Mushrooms Inc.

Mushrooms has a vision to support the growth of the mushroom industry through collaboration, innovation and development. Creating and supporting environmentally beneficial product innovation is at the heart of Mushrooms Inc. The company’s current focus is on the industrial application of mycelium for the creation of carbon-neutral products for the building and healthcare industries as well as for creating supplements based on the proven health benefits of mushrooms. Research and development is the path to achieving great innovation, and pioneers are the ones the company looks to for their fortitude and enduring dedication to the world of mycology. The working relationships Mushrooms fosters will result in scientifically proven products that advance the health of body, mind and environment. To learn more about the company, visit www.MushroomsInc.com.

Mushrooms Inc. (MSRM), closed Tuesday's trading session at $0.035, up 2.6393%, on 143,802 volume. The average volume for the last 3 months is 458,233 and the stock's 52-week low/high is $0.015/$0.11945.

Cheetah Net Supply Chain Service Inc. (CTNT)

We reported earlier on Cheetah Net Supply Chain Service Inc. (CTNT), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Cheetah Net (NASDAQ: CTNT), a supplier of parallel-import vehicles sourced in the U.S. to be sold in the PRC market, recently announced the closing of its initial public offering of 1,250,000 shares of Class A common stock. The company secured gross proceeds of $5.0 million, with each share of Class A common stock sold at an offering price of $4.00. In addition, Cheetah Net granted the underwriters a 45-day option to purchase up to an additional 187,500 shares of Class A common stock to cover over-allotments at the initial public offering price, less the underwriting discount. The Class A shares began trading under the symbol CTNT on the Nasdaq Capital Market on Aug. 1, 2023. Maxim Group LLC acted as sole book-running manager for the offering. Hunter Taubman Fischer & Li LLC acted as U.S. counsel to the company, and Loeb & Loeb LLP acted as U.S. counsel to Maxim Group LLC in connection with the offering.

To view the full press release, visit https://ibn.fm/HlAdl

About Cheetah Net Supply Chain Service Inc.

Cheetah Net is a supplier of parallel-import vehicles sourced in the U.S. to be sold in the PRC market. In the PRC, parallel-import vehicles refer to those purchased by dealers directly from overseas markets and imported for sale through channels other than brand manufacturers’ official distribution systems. To the company’s knowledge, there are currently no U.S. federal or state laws, regulations or rules on trade or export that prohibit the export of vehicles that will be parallel imported into foreign countries. The company purchases automobiles, primarily luxury brands such as Mercedes, BMW, Porsche, Lexus, and Bentley, from the U.S. market and resells them to the company’s customers, including both U.S. and PRC parallel-import car dealers. The company derives profits primarily from the price difference between the company’s buying and selling prices for parallel-import vehicles.

Cheetah Net Supply Chain Service Inc. (CTNT), closed Tuesday's trading session at $2.4, off by 15.493%, on 503,093 volume. The average volume for the last 3 months is 148,256 and the stock's 52-week low/high is $N/A/$N/A.

Adamas One Corp. (JEWL)

WallStreetNation, Small Caps, InsiderTrades and bullseyeoptiontrading reported earlier on Adamas One Corp. (JEWL), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Adamas (NASDAQ: JEWL), The Original Lab-Grown Diamond Company(TM), is a high-tech company that leverages proprietary technology to produce high-quality, single-crystal, lab-grown diamonds for jewelry and diamond materials for industrial uses. The company today announced its entry into a non-binding letter of intent (“LOI”) to acquire a key lab-grown diamond manufacturer, Flawless Allure Grown Diamonds, LLP (“FAGD”). “This acquisition will solidify our position as a leader in the lab-grown diamond industry based on our capabilities to vertically integrate, produce and market lab-grown diamonds,” said Adamas One CEO Jay Grdina. “Our goal has been to complete our ecosystem and become as self-sufficient as possible, and the acquisition of Flawless, one of the top diamond cut and polishers in the industry, completes our ability to control our end-to-end production, speed of production and time-to-marketing. This transaction represents a significant step in the execution of our strategy to ensure that we are well positioned in the market, with minimal to no shareholder dilution.”

To view the full press release, visit https://ibn.fm/3E5pq

About Adamas One Corp.

Adamas is a lab-grown diamond manufacturer that, in its facilities in Greenville, South Carolina, produces near flawless single-crystal diamonds for gemstone and industrial applications. The company holds 36 patents and uses its proprietary chemical vapor deposition (“CVD”) to grow gem-sized and smaller diamond crystals. Adamas One(TM) lab-grown diamonds have the same physical, chemical and optical properties as mined diamonds. The company’s controlled manufacturing processes enables it to produce very high-quality, high-purity, single-crystal colorless, near colorless and fancy colored Type IIA diamonds to suit a variety of industrial and gemstone applications. The company intends to market and sell its diamonds into the wholesale jewelry and industrial markets. For more information, visit www.AdamasOne.com.

Adamas One Corp. (JEWL), closed Tuesday's trading session at $1.395, off by 1.7606%, on 152,276 volume. The average volume for the last 3 months is 3.111M and the stock's 52-week low/high is $0.6901/$11.94.

The QualityStocks Company Corner

Knightscope, Inc. (NASDAQ: KSCP)

The QualityStocks Daily Newsletter would like to spotlight Knightscope, Inc. (NASDAQ: KSCP).

Knightscope, Inc. [Nasdaq: KSCP] ("Knightscope" or the "Company"), a leading developer of autonomous security robots and blue light emergency communication systems, today announced that it delivered on yet another important milestone when the Company deployed its first two K1 Hemisphere Autonomous Security Robots ("ASRs") at an undisclosed location in Hawaii for the final phase of product development – client testing. Knightscope will collect insightful feedback over the next several weeks from its evaluation client, a global brand of full-service hotels and resorts, who will put the Hemisphere through its paces in a real operating environment. Numerous pre-orders from a variety of clients are due to be fulfilled thereafter. "Criminals and terrorists can be anywhere. If we are to fulfill our mission, then Knightscope needs to be everywhere, both outdoors and indoors. Similar to our recently announced Automated Gunshot Detection ('AGD'), this all-new product continues the march towards significantly increasing our TAM ('Total Addressable Market') as the go to public safety innovator," said William Santana Li, chairman and CEO, Knightscope, Inc.

Knightscope, Inc. (NASDAQ: KSCP), founded in 2013 and based in Mountain View, California, is a leader in the development of autonomous security capabilities targeting to disrupt the $500 billion security industry. Knightscope’s technology uniquely combines self-driving technology, robotics, artificial intelligence and electric vehicles.

Knightscope designs and builds Autonomous Security Robots (ASRs) that provide 24/7/365 security to the places you live, work, visit and study. The company’s client list covers public institutions and commercial business operations, including multiple Fortune 1000 companies to date. These ASRs have been proven to enhance safety at hospitals, logistics facilities, manufacturing plants, schools and corporations. ASRs act as highly cost-effective complementary systems to traditional security and law enforcement officials, providing an additional advantage by continuing to offer uninterrupted patrolling capabilities across the country.

The company’s ASRs have assisted in the arrest of suspects involved in crimes ranging from armed robbery to hit-and-runs. Their machine-embedded thermal scanning capability even aided in preventing the breakout of a major fire. You can learn more about the crime fighting wins at www.knightscope.com/crime

The company has achieved several milestones since its creation in 2013, including:

  • Establishing itself in a 15,000-square-foot facility located in Mountain View, California, in the heart of Silicon Valley, where Knightscope designs, engineers and builds its technology (Made in the USA)
  • Operating for more than 1 million hours in the field and securing contracts across five time zones, from Hawaii to Rhode Island
  • Raising over $100 million since inception to build its technology from scratch and generating over $13 million in lifetime revenue, validating both the market opportunity and the technology

Growth Capital & Proposed Nasdaq Listing

With backing from more than 28,000 investors and four major corporations and over $100 million raised since inception, Knightscope is poised to be an industry leader in the future of public safety and security.

On December 1, 2021, Knightscope announced the commencement of an offering of up to $40 million of its Class A common stock, with shares to be listed immediately following closing on the Nasdaq Global Market under the ticker symbol ‘KSCP’. The offering is for up to 4 million shares priced at $10 per share. Learn more at www.knightscope.com/investors

Company Mission – Reimagining Public Safety

Knightscope’s long-term vision has an eye on the greater good. The company’s mission is to make the United States of America the safest nation in the world while supporting the 2+ million law enforcement and security professionals across the country.

Crime has an estimated negative economic impact in excess of $2 trillion annually. As crime is reduced, positive impacts will likely be realized across several aspects of society, including housing, financial markets, insurance, municipal budgets, local business and safety in general.

Knightscope CEO William Santana Li was interviewed by Kevin O’Leary, more commonly known as Shark Tank’s Mr. Wonderful. When asked to explain how the benefits provided by the ASRs outrank a human doing the same job, Li said, “First, just the simple presence of a physical deterrent causes criminal behavior to change. Second, the machines are self-driving cars that patrol all around and recharge themselves. They also generate 90 terabytes of data per year. No human would ever be able to process that. The robots are intended to be eyes and ears for the humans, not a one-to-one replacement.”

The Knightscope solution to reduce crime combines the physical presence of ASRs, sometimes referred to as proprietary Autonomous Data Machines, with real-time onsite data collection and analysis. The ASRs are fitted with eye-level 360° cameras, thermal scanning, public address announcements and various other features that work in tandem with humans to provide law enforcement officers and security guards unprecedented situational awareness.

Those 90 terabytes of data are then formatted in a useable way, so law enforcement can leverage that information and execute their responsibilities more effectively.

Public Safety Innovation

The company’s recurring revenue business model is set up to mimic the recurring societal problem of crime, and it takes into consideration the fact that innovation in the security and public safety industry has been stagnant for decades. Because the traditional practices of the sector have remained unchanged for years, automation has potential to drive substantial cost savings – and significant improvement in capabilities.

Human security guards are one of both the largest expenses and the largest liabilities for companies. Knightscope’s robots are offered at an effective price of $3 to $9 per hour, compared with approximately $85 for an armed off-duty law enforcement officer and $15 to $35 for an unarmed security guard.

This innovation has the potential to drive considerable cost savings. Based on these estimates, manufacturing costs can be recovered as soon as the first year of operation.

Product Offerings

The company has nine patents and a framework of unique intellectual property. Knightscope currently offers a K1 stationary machine, a K3 indoor machine and a K5 outdoor machine. A K7 multi-terrain four-wheel version is in development.

The ASRs autonomously patrol client sites without the need for remote control, providing a visible, force multiplying, physical security presence to help protect assets, monitor changes in the area and deter crime. The data is accessible through the Knightscope Security Operations Center (KSOC), an intuitive, browser-based interface that enables security professionals to review events generated by the ASRs providing effectively ‘mobile smart eyes and ears’. Learn more at www.knightscope.com/ksoc

The ASRs and the related technologies were developed ground up by the company and are Made in the USA.

The Robot Roadshow

Knightscope has created the ultimate hybrid physical and virtual event, bringing its Autonomous Security Robot technologies to cities across the country for interactive and in-person demonstrations.

Each roadshow landing is hosted virtually by a Knightscope expert, and visitors can interact directly with each of the company’s ASRs and see the Knightscope Security Operations Center (KSOC) user interface in action. Learn more at www.knightscope.com/roadshow

Management Team

Chief Executive Officer William Santana Li is a veteran entrepreneur, a former executive at Ford Motor Company and the founder of GreenLeaf, a company that grew to be the world’s second-largest automotive recycler and is now part of LKQ Corporation (NASDAQ: LKQ).

Chief Client Officer Stacy Dean Stephens brings his experience as a former Dallas law enforcement officer, as well as his skills as a seasoned entrepreneur, to assist on the client acquisition side.

Chief Intelligence Officer Mercedes Soria is an award-winning technologist and former Deloitte software engineer.

Chief Design Officer Aaron Lehnhardt brings over two decades of two- and three-dimensional product and industrial design in modeling and VR to the table, on top of his experience as a senior designer at Ford Motor Company.

Chief Financial Officer Mallorie Burke is a seasoned financial executive and strategic advisor for both private and publicly traded technology companies with a successful track record of mergers & acquisitions, corporate growth and exit strategies, including public listings.

General Counsel Peter Weinberg leverages 30 years of diverse corporate counsel experience, spanning from startups to well-established companies, private and public. He has significant experience training personnel at all levels in critical areas to improve corporate compliance and productivity.

Knightscope, Inc. (NASDAQ: KSCP), closed Tuesday's trading session at $1.24, up 9.7345%, on 3,148,264 volume. The average volume for the last 3 months is 58,560 and the stock's 52-week low/high is $0.36/$3.87.

Recent News

Lexaria Bioscience Corp. (NASDAQ: LEXX)

The QualityStocks Daily Newsletter would like to spotlight Lexaria Bioscience Corp. (NASDAQ: LEXX).

Lexaria recently celebrated the receipt of its 35th overall granted patent worldwide when the USPTO recently awarded US patent #11,700,875, titled "Compositions and Methods For Sublingual Delivery of Nicotine"

The company described the new patent as "strategically important"

The patent positions the company to tap into the growing oral nicotine market and offers protection in one of the world's leading oral nicotine markets

This patent could also lead to additional subsequent patents from within this family

Lexaria's DehydraTECH-nicotine formulation is patent granted for oral nicotine delivery in the US, Canada, and Australia

When Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, announced receipt of an Australian patent on March 8, 2022 (https://cnw.fm/41v9c), its resolve to continue expanding its intellectual property ("IP"), particularly within the oral nicotine sector, received a significant boost. The then-new Australian patent had expanded upon the company's IP rights to apply its DehydraTECH(TM) technology platform to most oral forms of nicotine. Still, the company intended to continue growing its existing portfolio, expanding IP protection to multiple other jurisdictions.

Lexaria Bioscience Corp. (NASDAQ: LEXX) is a global innovator in drug delivery platforms. The company’s patented technology, DehydraTECH™, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting healthier oral ingestion methods and increasing the effectiveness of fat-soluble active molecules. DehydraTECH promotes fast-acting, less expensive and more effective oral drug delivery and has been thoroughly evaluated through in vivo, in vitro and human clinical testing.

DehydraTECH is covered by 21 issued and more than 50 pending patents in over 40 countries around the world. Lexaria’s first patent was issued by the U.S. Patent and Trademark Office in October 2016 (US 9,474,725 B1), providing 20 years of patent protection expiring June 2034. Multiple patents have been awarded since then and are expected in the future.

Lexaria has a collaborative research agreement with the National Research Council (NRC), the Canadian government’s premier research and technology organization. The company has filed for patent protection for specific delivery of nicotine, vitamins, NSAIDs, testosterone, estrogen, cannabinoids, terpenes, PDE5 inhibitors (with brand names like Viagra), tobacco and more.

Lexaria began developing DehydraTECH in 2014 and has since continued to strengthen and broaden the technology. The company has no plans to create or sell Lexaria-branded products containing controlled substances. Instead, Lexaria licenses its technology to other companies around the world to offer consumers the best possible performance across an array of ingestible product formats.

The company’s technology is best thought of as an additional layer that providers of consumer supplements, prescription and non-prescription drugs, nicotine and CBD products can utilize to improve the effectiveness of their own existing or planned new offerings. Lexaria has licensed DehydraTECH to multiple companies, including a world-leading tobacco producer for the research and development of smokeless, oral-based nicotine products, and for use in industries that produce cannabinoid beverages, edibles and oral products.

DehydraTECH is suitable for use with a wide range of product formats including pharmaceuticals, nutraceuticals, consumer packaged goods and over-the-counter capsules, pills, tablets and oral suspensions.

DehydraTECH Technology

Lexaria’s DehydraTECH is designed specifically for formulating and delivering lipophilic (fat-soluble) drugs and active ingredients. DehydraTECH increases their effectiveness and improves the way active pharmaceutical ingredients enter the bloodstream. The major benefits to a subject ingesting a DehydraTECH-enabled drug or consumer product can be summarized by the following:

  • Speeds up delivery – the effects of the product are felt by the subject in just minutes.
  • Increases bioavailability – the technology is much more effective at delivering a drug or product into the bloodstream.
  • Increases brain absorption – animal testing suggests significant improvement in the quantity of drug delivered across the blood-brain barrier.
  • Improves drug potency – more of the ingested product is made available to the body, so lower doses are required to achieve the desired effect.
  • Reduces drug administration cost – lower doses mean lower overall drug costs.
  • Masks unwanted taste – the technology eliminates or reduces the need for sweeteners.

Lexaria has demonstrated in animal studies a propensity for DehydraTECH technology to elevate the quantity of drug delivered across the blood-brain barrier by as much as 1,900 percent, initiating additional new patent applications and opening possibilities for improved drug delivery.

Since 2016, DehydraTECH has repeatedly demonstrated, with cannabinoids and nicotine, the ability to increase bio-absorption by up to five to 10 times, reduce time of onset from one to two hours to just minutes, and mask unwanted tastes. The technology is to be further evaluated for additional orally administered bioactive molecules, including antivirals, cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs) and nicotine.

Market Outlook

Lexaria’s ongoing research and development efforts are mainly focused on development of product candidates across several key segments:

  • Oral Cannabinoids – a market estimated to be worth $18.4 billion in 2021 and expected to reach $46.2 billion by 2025.
  • Antivirals – an estimated $52.1 billion market in 2021 that’s expected to grow to $66.7 billion by 2025.
  • Oral Mucosal Nicotine – smokeless tobacco products, a $13.6 billion market in 2018, is forecast to grow at 7.2 percent annually through 2025.
  • Human Hormones – estrogen and testosterone replacement therapies represented a $21.9 billion market in 2019, with a forecast CAGR of 7.7 percent through 2027.
  • Ibuprofen and Naproxen – NSAID sales totaled $15.6 billion globally in 2019 and are projected to reach $24.4 billion by 2027.
  • Vitamin D3 – the global market size was $1.1 billion in 2021, growing at 7 percent per year and expected to reach $1.7 billion in 2026.

Management Team

Chris Bunka is Chairman and CEO of Lexaria Bioscience Corp. He is a serial entrepreneur who has been involved in several private and public companies since the late 1980s. He has extensive experience in the capital markets, corporate governance, mergers and acquisitions, as well as corporate finance. He is named as an inventor on multiple patent innovations.

John Docherty, M.Sc., is the President of Lexaria. He is a pharmacologist and toxicologist, and a specialist in the development of drug delivery technologies. He is the former president and COO of Helix BioPharma Corp. (TSX: HBP). He is named as an inventor on multiple issued and pending patents.

Greg Downey is Lexaria’s CFO. He has more than 35 years of diverse financial experience in the mining, oil and gas, manufacturing, and construction industries, and in the public sector. He served for eight years as CFO for several public companies and has provided business advisory and financial accounting services to many large organizations.

Gregg Smith is a strategic advisor to Lexaria. He is a founder and private investor with Evolution VC Partners. He is a member of the Sand Hill Angels and held previous investment banking roles with Cowen and Company and Bank of America Merrill Lynch.

Dr. Philip Ainslie serves as a scientific and medical advisor to Lexaria. He is co-director for the Centre for Heart, Lung and Vascular Health, Canada. He is also Research Chair in Cerebrovascular Physiology and Professor at the School of Health and Exercise Sciences, Faculty of Health and Social Development at the University of British Columbia.

Lexaria Bioscience Corp. (LEXX), closed Tuesday's trading session at $0.9299, up 5.6705%, on 58,706 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $3.87/$.

Recent News

IGC Pharma Inc. (NYSE American: IGC)

The QualityStocks Daily Newsletter would like to spotlight IGC Pharma Inc. (NYSE American: IGC).

In the border regions between Idaho and Oregon, there exist stark differences in cannabis legislation. While Oregon allows for the legal purchase of cannabis, Idaho stands as one of the few states that have yet to adopt any form of legalized cannabis. Amid this backdrop, an organization known as Kind Idaho is firmly devoted to championing cannabis's potential as a medicinal solution.

Led by Joe Evans, the treasurer of Kind Idaho, the political action committee and nonprofit organization, founded in 2021, is unwaveringly committed to the cause of medical cannabis legalization. Evans clarifies that the group's sole focus is on medical cannabis as opposed to advocating for full decriminalization or casual use for ailments such as headaches.

Recently, Representative John Vander Woude introduced the Idaho Medical Marijuana Act, a narrow proposal aiming to spark discussions heading into 2024. The act, however, met criticism from Evans and his supporters because it offers extremely limited access to medical cannabis, restricting it to ingestible forms such as chewables, tablets, pills or droplets, with a maximum of 10 mg of tetrahydrocannabinol. The struggles that some states such as Idaho go through to have marijuana legalized for medical purposes can partially be addressed if more companies such as IGC Pharma Inc. (NYSE American: IGC) invest in developing pharmaceutical-grade formulations approved by the FDA so that the patients who need these treatments can obtain them through the mainstream medical system.

IGC Pharma Inc. (NYSE American: IGC), through subsidiary IGC Pharma, develops, patents, and markets advanced THC-based drug formulations for the treatment of symptoms related to various diseases including but not limited to Alzheimer’s disease, Tourette syndrome, chronic pain, and pet seizures.

IGC’s leading drug candidate, IGC-AD1, has completed Phase 1 of a safety and tolerability trial and entered Phase 2 trials for treating agitation in patients with Alzheimer’s dementia, the first study in humans of a natural tetrahydrocannabinol (THC) compound plus another molecule (www.clinicaltrials.gov). As of September 2022, the IGC trial is the only ongoing Phase 2 trial of a natural THC-based formulation on Alzheimer’s patients.

The company’s other drug candidate, TGR-63, is an enzyme inhibitor that has shown in preclinical trials the potential to reduce neurotoxicity in Alzheimer’s cell lines. Both drug candidates have shown their ability to ameliorate beta amyloid plaques in Alzheimer’s cell lines and improve memory in Alzheimer’s mouse models. Beta amyloid plaques are a key hallmark of Alzheimer’s and an important target of Alzheimer’s pharmaceutical drug development.

Neuro Psychiatric Symptoms (NPS) are not only debilitating for Alzheimer’s patients; they also place an immense emotional burden on their caregivers. Beyond reducing symptoms, IGC-AD1’s active molecules and TGR-63 have also shown promise in preclinical trials to reduce important hallmarks of Alzheimer’s including plaques and tangles, as well as improving the treatment of memory loss.

Over the past eight years, the IGC team has amassed a deep knowledge of cannabinoid science, including extraction, isolation, purification, and development. The company’s strategy is to leverage its unique end-to-end capabilities, platform, and expertise to develop a class-leading program and bring it to market quickly and cost efficiently to treat neurodegenerative diseases such as Alzheimer’s.

The company also has a family of cannabidiol (CBD)-based consumer products (www.Holief.com) such as pain relief creams, pain relief gels, purpose gummies, tinctures, and capsules targeting women’s wellness, with a particular focus on premenstrual syndrome (PMS) and dysmenorrhea (period cramps). In addition, the company targets individuals that need sleep-aids with its specially formulated low melatonin cannabinoid gummies.

IGC has also introduced a low-calorie CBD- and caffeine-infused energy beverage brand (www.SundaySeltzer.com) that is currently available for purchase. The company’s brands are founded on the belief that effective natural solutions should be affordable and accessible to everyone. As the demand for natural products targeting women’s wellness and energy drinks continue to grow, these products are seeing strong traction in the market.

The company operates three facilities – a large GMP (Good Manufacturing Production Standards) certified facility that includes extraction, distillation, and manufacturing, in Washington State; a GMP-211 (pharmaceutical) grade facility in Maryland; and a facility licensed for controlled substances including cannabis in Bogota, Colombia, with complete access to legal licensed cannabis where the company conducts its testing.

In addition, the company’s development under Magistral Formulations is approved by INVIMA (Colombia National Food and Drug Surveillance Institute) to treat neurological disorders, non-oncological chronic pain, and mental disorders.

IGC’s intellectual property (IP) portfolio comprises of eight patents that it controls and seven patent applications. The portfolio includes #11,446,276, a patent for extreme low dose THC treatment of Alzheimer’s that was granted in September 2022.

The company is headquartered in Potomac, Maryland.

IGC-AD1

IGC-AD1 is the company’s leading drug candidate for the treatment and relief of Alzheimer’s symptoms. A significant amount of research on Alzheimer’s cell lines has shown that the active agents in IGC-AD1 reduce plaques and neurofibrillary tangles that are the hallmarks of Alzheimer’s. Further, micro-dosing of THC, as shown in cell lines, could increase the functioning of mitochondria and potentially promote the growth of new neural pathways (neurogenesis). The research shows that micro-dosing of THC affects the brain radically differently from the normal higher dosing of THC.

While there is a significant body of research showing that THC is neuro-toxic at normal levels of dosing, micro-dosing of THC has been shown to be non-toxic to neurons. With the results of these preclinical studies, the company developed an oral formulation, IGC-AD1. The company recently completed a safety and tolerability Phase 1 trial on Alzheimer’s patients and has initiated a Phase 2, multi-site, double-blind, randomized, placebo-controlled trial of the safety and efficacy of IGC-AD1 on agitation in participants with dementia due to Alzheimer’s disease at sites in the U.S. and Canada. IGC expects the Phase 2 trial to take between 9 and 12 months to complete, barring unknown factors such as, for example, a resurgence of COVID and the enforcement of lockdowns and travel restrictions.

With further successful trials and FDA approvals, IGC hopes to bring a drug based on natural THC as an effective treatment for agitation in Alzheimer’s to market.

TGR-63

The company’s other molecule, TGR-63, has been shown to reduce the neurotoxicity that impacts memory loss in preclinical trials with mice. On a dose dependent manner, transgenic Alzheimer’s mice treated with TGR-63 showed improvement in memory relative to control.

Both drug candidates, IGC-AD1 and TGR-63, have shown their ability to reduce the brain plaques associated with memory loss in Alzheimer’s in mice.

With further successful trials and FDA approvals, IGC hopes to bring TGR-63 as a treatment for Alzheimer’s disease to market.

Market Opportunity

Alzheimer’s disease impacts over 55 million people worldwide and about 5.5 million individuals in the U.S. Over 70% of these patients face debilitating symptoms, including anxiety, depression, and agitation (Mendez, 2021). Agitation in dementia patients can include excessive physical movement and verbal activity, restlessness, pacing, belligerence, aggression, screaming, crying, and wandering.

In 2020, the estimated healthcare costs for Alzheimer’s disease in the U.S. were $305 billion. Medicare and Medicaid covered about 70% of those costs, leaving considerable burden on patients and families. At the current rate of growth of Alzheimer’s and other dementia diagnoses, those costs are estimated to reach over $1 trillion by 2050.

Currently, there are no FDA-approved medications to alleviate the symptoms of dementia due to Alzheimer’s disease, providing a tremendous opportunity for formulations that can have an impact on quality of life and disease progression.

Management Team

Richard Prins has been chairman at IGC since 2012 and served as an independent director since 2007. From March 1996 to 2008, he was the Director of Investment Banking at Ferris, Baker Watts, Incorporated. Prins served in a consulting role to RBC until January 2009. He currently volunteers full time with a non-profit organization, Advancing Native Missions, and is a private investor. Since February 2003, he has been on the board of Amphastar Pharmaceuticals Inc. He holds a bachelor’s degree from Colgate University and an MBA from Oral Roberts University.

Ram Mukunda is CEO and President of IGC. He has been the chief inventor and architect of most of the company’s patent filings and is responsible for the company’s strategic positioning. Prior to IGC, he was founder and CEO of Startec Global Communications, which he took public in 1997. He served as Strategic Planning Advisor at Intelsat, a communications satellite services provider. From 2001 to 2003, he was a Council Member at Harvard’s Kennedy School of Government, Belfer Center of Science and International Affairs. He was named the 1998 Ernst & Young Entrepreneur of the Year. He holds bachelor’s degrees in electrical engineering and mathematics, and a master’s degree in engineering from the University of Maryland.

Dr. Jagadeesh Rao is the company’s Principal Scientist. His career spans two decades in the public sector and product R&D for Johnson & Johnson. He leads IGC’s scientists in the development of pharmaceutical and OTC products. He worked for the federal National Institutes of Health, and for the National Institute on Drug Abuse. His Ph.D. in Neurochemistry is from the National Institute of Mental Health & Neurosciences in India. He did postdoctoral training at the University of Illinois-Chicago.

Claudia Grimaldi is a Director, Vice President, Principal Financial Officer, and Chief Compliance Officer for IGC. She also serves as a Director/Manager Director for some of the company’s subsidiaries. She graduated with highest honors from Javeriana University in Colombia with a bachelor’s degree in psychology. She holds an MBA, graduating with highest honors, from Meredith College in North Carolina. In addition, she has attended the Darden School of Business Financial Management Executives program and the Corporate Governance Program at Columbia Business School. She is currently pursuing her Directorship Certification with the National Association of Corporate Directors. She is fluent in both English and Spanish.

IGC Pharma Inc. (NYSE American: IGC), closed Tuesday's trading session at $0.3555, up 1.2821%, on 261,261 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.2785/$0.74.

Recent News

HeartBeam Inc. (NASDAQ: BEAT)

The QualityStocks Daily Newsletter would like to spotlight HeartBeam Inc. (NASDAQ: BEAT) .

HeartBeam (NASDAQ: BEAT) is a cardiac technology company that has developed the first and only credit card-size 3D-vector electrocardiogram ("VECG") platform for patient use at home, allowing for the creation of rich data for AI. The company today announced its appointment of Deborah Castillo, PhD, as vice president of regulatory affairs. An experienced biomedical engineer with extensive knowledge of FDA, EU and Health Canada regulations, Castillo has significant expertise in cardiovascular diseases, neuroscience and medical devices that support these functions. Prior to joining HeartBeam, Deborah served as director of regulatory affairs neuromodulation at LivaNova, a global medical device company creating neuromodulation devices and cardiopulmonary products, developing and implementing the regulatory strategies for various Class III devices. "We are privileged to have Deborah join HeartBeam as a strong addition to our senior leadership team," said Branislav Vajdic, Ph.D., CEO and founder of HeartBeam. "She is a seasoned regulatory leader with a proven track record of bringing novel medical technologies to market. Her expertise will be invaluable in leading our regulatory strategy and execution."

To view the full press release, visit https://ibn.fm/InadG

HeartBeam Inc. (NASDAQ: BEAT) is a cardiac technology company that has developed the first and only 3D-vector 12-lead electrocardiogram (ECG) platform for heart attack detection anytime, anywhere. The company’s proprietary ECG telehealth technology aims to redefine the way high risk cardiovascular patients are diagnosed in ambulatory and acute care settings. HeartBeam’s initial focus is on providing diagnostic data to help physicians with care management of patients with cardiovascular disease.

In August 2022, HeartBeam announced that it submitted its HeartBeam AIMI™ software for approval from the U.S. Food and Drug Administration (FDA). HeartBeam AIMI is a platform technology to improve the speed and accuracy of heart attack detection in acute care settings. The company expects FDA approval by the end of 2022, and a full commercial roll-out of HeartBeam AIMI is targeted for Q1 2023.

HeartBeam sees submission of its first product based on its platform technology as an important milestone toward commercialization, which underscores the company’s continued progress toward making the HeartBeam AIMI platform widely available to help emergency department physicians quickly and accurately identify a heart attack.

While the FDA conducts its regulatory review, HeartBeam will focus on executing key components of its commercialization plan and subscription revenue model. It will also continue to engage in discussions with strategic institutions, including academic centers, regional healthcare systems and regional community hospital systems that can utilize HeartBeam products.

The company is based in Santa Clara, California.

Products

HeartBeam’s development portfolio includes two products:

  • HeartBeam AIMI is software that provides a 3D comparison of baseline and symptomatic 12-lead ECG to more accurately identify a heart attack in acute care settings and, as noted above, has been submitted for FDA approval; and
  • HeartBeam AIMIGo™, the first and only credit card-sized 12-lead output ECG device coupled with a smartphone app and cloud-based diagnostic software system for remote heart attack detection.

HeartBeam is developing AIMIGo, a medical-grade detection and monitoring technology for use in remote heart attack detection, thereby allowing physicians to diagnose a patient’s heart attack as it occurs, even if the patient is not at a medical facility. The company’s system, once approved by the FDA, can be used by patients at home or almost anywhere and anytime to help their physicians assess whether chest pain is the result of a heart attack or another cause. While approximately 82% of chest pain ED visits are unnecessary, patients delay approximately 3 to 4 hours after symptoms begin, increasing mortality rates by 40%. The company’s goal is to shorten the time to treatment outside of the medical facility to improve patients’ well-being.

HeartBeam’s AIMIGo is a powerful, portable and easy-to-use prescription-based product. It comprises a smartphone app, a credit card-sized ECG device placed on a patient’s chest, the HeartBeam cloud platform, and a digital portal for the physician to view ECG results and direct patient action. For the first time outside of a medical setting, HeartBeam AIMIGo enables patients and their clinicians to determine if symptoms are due to a heart attack, quickly and easily, so care can be expedited, if needed.

Pending FDA clearance, AIMIGo is initially intended to be available by prescription, and is reimbursable under existing remote patient monitoring codes (RPM codes). This provides a new revenue stream to physicians who before did not have a way to monitor these high-risk patients. The RPM codes provide a monthly reoccurring revenue stream to the company, as well. On average, at current reimbursement rates, the practice will receive $1,300+ per year per patient they monitor, and the company will receive $600 per year per patient from this RPM reimbursement.

Market Overview

Adoption rates of telehealth services increased dramatically in recent years, with the COVID-19 pandemic serving as a major driver of growth. Among the areas seeing the greatest expansion are cardiology, radiology, behavioral health and online consultation.

Encouraging this growth, governments are actively developing new policies and reimbursement guidelines to promote the use of digital health platforms. The U.S. Centers for Medicare & Medicaid Services (CMS), for example, has recently expanded reimbursement for telehealth services. U.S. market growth is also being driven by the rising prevalence of chronic conditions and the growing geriatric population.

Remote heart attack detection is a previously unsolved problem with a massive and underserved market that is several times larger than the $2 billion total addressable market (TAM) in the U.S. for ECG cardiac arrhythmia monitoring.

Approximately 8 million Americans have suffered at least one heart attack, and a total of 18 million have been diagnosed with coronary artery disease (CAD). Based on these figures, HeartBeam projects a total addressable U.S. market TAM valued at $10 billion annually for its AIMIGo solution for remote heart attack monitoring of CAD.

Management Team

Branislav Vajdic, Ph.D., Chief Executive Officer and Founder of HeartBeam, Inc, combines over 30 years of experience in technology development and senior management positions. Dr. Vajdic has been deeply involved with the development of HeartBeam’s technology to fit his vision for the company. Prior to HeartBeam, from 2007 to 2010, Dr. Vajdic was CEO and Founder of NewCardio, a publicly traded company in the cardiovascular devices space. From 1984 to 2007, Dr. Vajdic was at Intel, where he held various senior management position. At Intel, Dr. Vajdic was the designer of first Flash memory and two key inventions that enabled Flash as a product and led engineering groups responsible for Pentium 1 through Pentium 4 designs. Dr. Vajdic was awarded two Intel Achievement Awards, the highest level of award for outstanding contributions to Intel. Dr. Vajdic is author of numerous patents and publications in the fields of cardiovascular devices, as well as chip design. Dr. Vajdic holds a Ph.D. in Electrical Engineering from the University of Minnesota.

Jon Hunt, Ph.D., has over 35 years’ experience in the medical/medical device industry with extensive domestic and international experience in general management, clinical/regulatory, sales and marketing. He also has diverse experience in Fortune 500 companies, as well as start-up environments. Dr. Hunt was the Vice President of Clinical Science and Technology, Medical Device Innovation Consortium, from July 2019 to July 2021, and Vice President of Clinical and Regulatory Affairs, Cryterion Medical from January 2018 to June 2019 (acquired by Boston Scientific Corporation in July 2018 for $202M). Dr. Hunt was the Founding President and CEO of Bardy Diagnostics, Inc. from October 2013 to November 2017 (acquired by Hill-Rom Holdings, Inc.). Prior to joining Bardy Diagnostics, Dr. Hunt spent the previous 11 years as the Vice President of Clinical & Regulatory Affairs with Cameron Health, Inc. (acquired by Boston Scientific Corporation). Dr. Hunt spent the previous 10 years with Cardiac Pacemakers, Inc., St. Jude Medical and Cardiac Pathways Corporation. Dr. Hunt began his career with Cardiac Pacemakers, Inc. (now Boston Scientific Corporation) as the Director of Clinical Programs. He subsequently held positions at St. Jude Medical in Clinical Affairs and as the Business Unit Director for the Cardiac Rhythm Management division for Europe, the Middle East and Africa. At Cardiac Pathways Corporation, Dr. Hunt held various executive positions as Vice President of International Sales and Marketing and Vice President of Worldwide Sales and Marketing (acquired by Boston Scientific Corporation). Dr. Hunt received his Ph.D. in Motor Control from The Pennsylvania State University, his Master’s from California State University, Long Beach and his undergraduate degree from Keele University in the United Kingdom.

Rick Brounstein, HeartBeam’s Chief Financial Officer, combines over 30 years of experience in health technology senior management. Since 2017, Mr. Brounstein has been and is currently a partner of Hardesty, LLC, a financial services firm, and Mr. Brounstein is currently a managing director of CTRLCFO, LLC, a firm Mr. Brounstein founded in 2016 to support funded start-ups in life science and technology. From 2008 to 2011, Mr. Brounstein was Chief Financial Officer of NewCardio, Inc., a microcap public company in the cardiology space, and, over his career, he has been with nine other companies in life science or technology, holding positions including Chief Financial Officer, Chief Operating Officer, Treasurer and Accounting Manager. From June 2001 through November 2007, Mr. Brounstein held several positions at Calypte Biomedical Corporation, a publicly traded medical device company, including Chief Financial Officer and Executive Vice President. In January 2007, Mr. Brounstein was appointed as the National Member Representative for the 2007 COSO Monitoring Project, which published new guidelines for monitoring internal financial controls in February 2009; Mr. Brounstein subsequently was a member of the FEI task force that issued the updated COSO Internal Control Framework in 2013. In March 2005, Mr. Brounstein was appointed to the SEC Advisory Committee on Smaller Public Companies. Mr. Brounstein earned his Certified Public Accountant (CPA) certification while working at Arthur Andersen LLP, formerly a public accounting firm. Mr. Brounstein holds a B.A. in accounting and an M.B.A. in finance, both from Michigan State University.

Ken Persen, HeartBeam’s Chief Technology Officer, combines over 28 years of experience in the medical device and digital health industries in engineering and senior management positions. Mr. Persen has been involved in several companies in Cardiac Rhythm Management, holding positions including Chief Executive Officer, Chief Technology Officer, Executive Vice President and Director of Engineering. Since 2016 and prior to joining HeartBeam, Mr. Persen was the Chief Technology Officer at LIVMOR, Inc., a digital health company. In addition, from 2016 through November 2021, he was also Chief Executive Officer of LIVMOR. Prior roles included Director of Engineering at Cameron Health (acquired by Boston Scientific), a late-stage medical device start up, and engineering and management positions at Guidant Corp. (acquired by Boston Scientific), a large medical device manufacturer. He has an undergraduate degree from University of Minnesota, Duluth, with a BA in Computer Science.

HeartBeam Inc. (NASDAQ: BEAT), closed Tuesday's trading session at $2.77, even for the day, on 39,994 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $1.12/$6.74.

Recent News

Advanced Container Technologies Inc. (OTC: ACTX)

The QualityStocks Daily Newsletter would like to spotlight Advanced Container Technologies Inc. (OTC: ACTX).

Marijuana producers Columbia Care Inc. and Cresco Labs have announced the termination of a $2 billion merger between the two companies. First announced in March 2022, the merger would have seen Cresco Labs buy Columbia Care for $2 billion in an historic deal that would have resulted in the largest marijuana producer in the country. Executives from Cresco noted at the time that the resulting company had the potential to be as large as Johnnie Walker or Coca-Cola and dominate the increasingly lucrative cannabis industry. The merger was a major bet on the growth and future of the cannabis industry. However, it appears that executives from both companies don't see the merit of making any big bets in the sector. Cresco Labs CEO Charles Bachtell said that due to recent developments in America's state-legal marijuana industry, company leaders terminated the merger to protect the company's and shareholders' long-term interests. Cannabis may be generating billions of dollars in revenue per year, but players in the sector regularly deal with a myriad of issues that threaten their profitability and make it incredibly hard to operate in the cannabis market. For instance, due to federal prohibition, the sector has barely any access to financial institutions and cannot rely on banks to facilitate contactless payments. This has led to many cannabis operators relying on a cash-only basis and increased the risk of violent robberies in retail cannabis establishments. According to Bachtell, the industry is currently going through a "tough economic time" and Cresco would be better served focusing on its core business. These tough economic conditions could also be impacting the operations of numerous ancillary entities, such as Advanced Container Technologies Inc. (OTC: ACTX), which do significant business with marijuana operators.

Advanced Container Technologies Inc. (OTC: ACTX) is in the business of selling and distributing self-contained, automated, indoor “micro-farms” called Grow Pods, along with related equipment and supplies. Additionally, the company designs and sells patented proprietary medical-grade plastic containers, known as the Medtainer®, that store and grind pharmaceuticals, herbs, teas and other solids or liquids.

ACTX is the leading distributor of Grow Pods. With a controlled environment, food and herbs can be grown without pesticides, harmful chemicals or risk of pathogen contamination, and with low energy consumption. Restaurants, grocery stores, non-profits, MSOs and entrepreneurs can use Grow Pods to ensure a fresh supply of ultra-clean produce year-round.

The company entered the Grow Pod business in October 2020 with its acquisition of all shares of Advanced Container Technologies Inc., a California corporation. As of February 28, 2022, ACTX is exploring the acquisition of the assets and the assumption of some or all of the liabilities of GP Solutions Inc., the developer and manufacturer of Grow Pods, for which ACTX is currently the sole U.S. distributor.

Because Grow Pods can be located almost anywhere, produce can be grown closer to the point of consumption and harvested at its peak, providing nutritious fruits and vegetables where needed. Indoor micro-farms, utilizing a practice known as vertical farming, have attracted the attention of governments and universities, which are now promoting vertical farming as a way to combat food insecurity and inequities.

The United States Department of Agriculture (USDA) has stated that vertical farming “is no longer a futuristic concept.” The department is enthusiastic about vertical farming, particularly those utilizing repurposed shipping containers, such as Grow Pods. Arizona State University reports that vertical farming reduces water use by 90 percent compared to conventional farming but produces 10 times the crop yield.

Products

Grow Pods

One of the company’s main business units is focused on selling advanced, self-contained hydroponic containers called Grow Pods. These unique and innovative automated systems are essentially micro-farms that can be placed virtually anywhere and, with their controlled and specially filtered environment, allow cultivation of a wide variety of crops, 365 days a year. The Grow Pod controlled environment offers major advantages for the production of high-value crops. The ability to grow year-round and the ability to cultivate in a smaller footprint using less water and power are some of the primary advantages of the system. Grow Pods offer constant temperature, humidity and airflow control, as well as automated watering and lighting schedules for optimal growth and minimal labor requirements, regardless of crop.

Containers

ACTX meets the needs of the pharmaceutical and medical markets, including the cannabis and hemp industries, with patented packaging systems. The company designs, customizes, brands and sells proprietary medical grade plastic containers that can store pharmaceuticals, herbs, teas and other solids or liquids, with a special built-in feature that can grind solids and shred herbs. The company’s flagship container product is the patented Medtainer®, a child resistant, medical-grade herb container and grinder that is water-tight, air-tight and smell proof. Packaging in the cannabis industry is critical, with numerous stringent regulations about how cannabis products must be packaged and labeled. ACTX also offers custom-branded, compliant vacuum seal bags and other retail container solutions.

Equipment and Supplies

ACTX markets and sells two principal products: Grow Pods, which are specially modified insulated shipping containers manufactured by GP Solutions Inc., in which plants, herbs and spices may be grown hydroponically in a controlled environment, and Medtainers®, which may be used to store pharmaceuticals, herbs, teas and other solids or liquids and can grind solids and shred herbs. The company also markets and sells various products related to Grow Pods and the Medtainer®, as well as providing private labeling and branding services for purchasers of Medtainers® and certain related products.

GP Solutions manufactures and sells other products, such as humidity controllers and LED lighting systems for vertical farming. The company’s specially designed lighting panels are programmed to emit the exact wavelength of light that each crop requires. The system has a daybreak-to-nightfall feature that gives plants the proper chromatic signals to grow rapidly and fruitfully. High efficiency LED light strips supply the crops with a red and blue light spectrum required for photosynthesis in the spectrum that plants need most.

Market Overview

The global vertical farming market is expected to reach $33.02 billion by 2030, according to a new report by Grand View Research. The market is forecast to expand at a CAGR of 25.5 percent from 2022 to 2030, according to Grand View. Escalating production of biopharmaceutical products, including cannabis, is anticipated to drive the market. The building-based segment of the market is expected to register a significant CAGR of 27.8 percent over the projected period. In addition, the climate control segment is expected to see high growth.

The global cannabis packaging market is expected to reach $14.34 billion by 2028, according to analysis by Reports and Data. The analysis forecasts 1,700 percent growth in cannabis users by the end of 2026, with packaging likely observing a whopping 26.42 percent growth in the forecast period. There are significant barriers to entry in the cannabis packaging market, giving an advantage to companies already established in the sector. These barriers include developing a thorough knowledge of the myriad regulations that govern cannabis packaging (which differ in each state), and child-resistance requirements.

Management Team

Douglas P. Heldoorn is the Founder and Chairman of Advanced Container Technologies Inc. He also holds the positions of President, CEO and COO at the company. Mr. Heldoorn has served on the Board of Directors since its inception in 2013. He has also previously held the position of Executive General Manager at Nissan Motor Corp.

Jeffory A. Carlson is CFO and Treasurer of ACTX. Mr. Carlson has also served as the company’s Corporate Controller since 2014.

Advanced Container Technologies Inc. (OTC: ACTX), closed Tuesday's trading session at $0.21, even for the day, on 10 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.0141/$0.65.

Recent News

GEMXX Corp. (OTC: GEMZ)

The QualityStocks Daily Newsletter would like to spotlight GEMXX Corp. (OTC: GEMZ) .

The company offers an approach that gives them a cost-saving edge over other producers in the market

Preliminary discussions have been made to shortlist engineering firms capable of conducting the necessary SK-1300 technical reports for the company's newest gold and Ammolite assets – with anticipated completion by the end of FY-2023

GEMXX is participating in Regulation A financing, and interested investors, shareholders, institutions, and financiers, are urged to visit the company's website for more information

GEMXX (OTC: GEMZ), a leader in the Ammolite Gems mine-to-market segment, recently announced its entry into an Ammolite Master Supply Agreement ("MSA") with Canadian Ammolite Gems by Kenneth Bradley. Kenneth Bradley, who hosts multiple live, on-air events annually featuring unique Ammolite jewelry designs, is one of the world's most recognized Ammolite experts and is a Canadian influencer with a global following that continues to grow. "This Ammolite supply agreement is a fundamental step in the company's expansion plans," Jay Maull, CEO and founder of GEMXX, said in the news release. "GEMXX and Kenneth Bradley share a goal of creating awareness and expanding the global market for GEMXX Ammolite gemstones."

To view the full press release, visit https://ibn.fm/4K9wj

GEMXX Corp. (OTC: GEMZ) is a mine-to-market enterprise specializing in gold, gemstone, and jewelry production. With ownership of mining resources, production facilities, and operational assets, the company maintains control over every aspect of its production process, from gold mining and gemstone extraction to jewelry manufacturing and global distribution.

As a prominent player in the industry, GEMXX stands out as a leading producer of high-quality finished Ammolite jewelry. Notably, it holds the distinction of being the sole public company engaged in Ammolite mining worldwide. In addition to its Ammolite operations, the company is actively involved in gold mining and prides itself on its ability to design and manufacture exquisite jewelry pieces and exceptionally rare, natural fossil decor items for clientele around the globe.

One of GEMXX’s key advantages lies in mining its own gold reserves to be utilized in its jewelry production. This strategic approach provides the company with a cost-saving edge over other producers in the market.

Ammolite is similar to black opal and is a biogenic gem like amber and pearl. It is derived from the fossilized shells of ammonites, a group of extinct marine nautiluses.

GEMXX’s world class gemstone cutters and jewelry designers are continuously leading the Ammolite industry. Its team believes in the company’s philosophy, vision and goals, and works every day to continue to drive the Ammolite industry to the forefront of the gem world.

The company has offices in Las Vegas and Hong Kong.

Projects and Operations

GEMXX has formulated an ambitious growth plan that, while challenging, is deemed attainable. The company’s strategy revolves around bolstering its market share through several key initiatives. Firstly, GEMXX aims to strengthen its position in current markets by nurturing and expanding existing relationships with customers and partners.

Secondly, the company plans to venture into untapped markets strategically. By identifying and targeting new areas, GEMXX seeks to establish a presence in regions that present promising opportunities for growth.

Additionally, GEMXX envisions growth through acquisitions. By considering and integrating key services, distribution networks and retail outlets into its fold, the company aims to consolidate its market position and capitalize on synergies for enhanced success.

To cater to the rising demand for its products, GEMXX has placed a primary focus on increasing gemstone production. The company’s southern properties, situated in Alberta, Canada, hold valuable deposits of rough Ammolite gemstone. By tapping into these resources, GEMXX is poised to meet the demand for its exquisite gemstone products and further fuel its expansion plans.

 

GEMXX possesses significant mineral assets in the form of a Mineral Work Permit covering an 800-acre area and two Ammonite Shell Mineral agreements encompassing 217 acres within the same region. The company’s management effectively operated mines in close proximity to these properties. Moreover, core sampling, along with fossil outcroppings on the riverbanks, confirms a substantial Ammolite resource present in these designated areas.

Both the Mineral Work Permit and the Ammonite Shell Mineral agreements grant GEMXX unrestricted access to all Ammolite resources within their respective demarcations. Notably, the company is not obligated to pay any royalties to third parties, thereby enabling GEMXX to fully capitalize on the potential of these valuable resources.

Furthermore, there are no stringent regulatory conditions that GEMXX must fulfill to gain or retain access to the Ammolite deposits. This freedom of access allows the company to proceed with its mining and production operations unimpeded, providing an advantageous position for future growth and success.

In March 2023, GEMXX made a significant announcement, revealing its acquisition of a 50% ownership stake in Crazy Horse Mining Inc., a Canadian gold mining company with assets situated in the province of British Columbia. As part of this deal, Crazy Horse’s assets, which encompass a 100% interest in two gold projects, called Snow Creek and Rosella Creek, spread across a substantial area exceeding 700 acres, now become part of GEMXX’s portfolio.

Under the terms of this strategic partnership, GEMXX and Crazy Horse will jointly share the expenses related to mining operations on these projects. Additionally, the two companies will share the gold produced from these ventures, leading to a collaborative and mutually beneficial arrangement.

Initial tests conducted on the property, combined with gold already recovered this season, confirm all expectations for the claims and substantiate the company’s estimated extraction target of over 100,000 ounces of easily recoverable gold. To validate and provide a more comprehensive assessment of this estimate, an S-K 1300-compliant Resource Report is scheduled to be conducted during the summer of 2023.

By acquiring this stake in Crazy Horse Mining Inc., GEMXX has positioned itself for further growth in the gold mining sector and is poised to capitalize on cost of goods savings in its jewelry business.

Market Opportunity

Leading independent market research companies such as Data Monitor and GIA estimate the worldwide market for luxury or premium lifestyle products, which include gems and jewelry, at over $90 billion annually and growing. Ammolite sales around the world have seen unprecedented growth over the past 20 years. Worldwide retail sales are now estimated to be over $100 million.

Ammolite jewelry and fossils are featured aboard cruise ships and can be found in specialty shops in almost every cruise port in North America. Asian markets have grown since feng shui master Edward Li called Ammolite the most influential stone of the new millennium, referring to it as the “Seven Color Prosperity Stone.” Home shopping channels in Japan, Australia, France, Germany, the UK, Canada and the U.S. have all featured Ammolite jewelry.

Ammolite and ammonites can also be found on many ecommerce sales platforms, including Amazon, eBay and Etsy. Ammolite is sold around the world in tourist and traditional jewelry markets. The company has established customers in home shopping channels, cruise tourism, jewelry retailers, Asian feng shui markets, Asian retail markets and ecommerce platforms.

Management Team

With over 160 years in Ammolite management, operations, and sales, GEMXX possesses an unparalleled wealth of knowledge and expertise. Its team members have extensive backgrounds in every facet of the Ammolite business, allowing the company to excel in product development, maintain rigorous quality control measures, and maximize profitability. The breadth and depth of the GEMXX team’s experience enable the company to navigate the industry with precision, ensuring that GEMXX remains at the forefront of the Ammolite market. GEMXX leverages its collective wisdom to drive innovation, deliver exceptional products, and optimize business strategies to achieve long-term success.

Jay Maull is Founder, CEO and Chairman of GEMXX. With a career spanning more than three decades, he has been deeply involved in the Ammolite industry, from mining and production to marketing. He has owned and operated the world’s largest Ammolite mine and has delivered exceptional Ammolite products to customers across all continents. He has also established the world’s largest Ammolite ecommerce platform.

Richard Clowater is President of GEMXX. He is a skilled sales and marketing professional with a focus on research, data analysis and strategic planning. He has successfully implemented initiatives to expand markets, boost profits and foster customer loyalty. He has an impressive track record of negotiating sales and contracts worth over $250 million with influential stakeholders, including key purchasing personnel, C-suite executives and government entities at all levels.

Tom Dryden is a Vice President of GEMXX and brings a wealth of experience and expertise to the production and marketing of Ammolite, spanning over 30 years. His extensive involvement in the industry has granted him unparalleled knowledge of the Bearpaw Ammonite bearing formations. As a recognized authority in the field, Mr. Dryden’s research and papers on Canadian Ammonites have garnered global recognition, being published worldwide. In his role at GEMXX, Mr. Dryden assumes the responsibility of overseeing the company’s Canadian-based production facilities. 

P. K. Chung is Business Manager Asia at GEMXX. With a track record of over 25 years in Ammolite business management, production and marketing in Asia, she is a recognized authority in the industry. Based in the Hong Kong gem district, she possesses an intricate understanding of the Asian gem and jewelry markets, including market dynamics, consumer preferences and industry trends specific to the region. Her strategic insights and deep connections enable GEMXX to thrive in this influential market.

GEMXX Corp. (OTC: GEMZ), closed Tuesday's trading session at $0.08, even for the day. The average volume for the last 3 months is and the stock's 52-week low/high is $0.053/$0.998.

Recent News

GolfLync Inc.

The QualityStocks Daily Newsletter would like to spotlight GolfLync Inc.

GolfLync, the trailblazing social media platform designed exclusively for golf enthusiasts, has witnessed a meteoric 15x membership increase over the past four months. This achievement is further solidified by GolfLync's outstanding performance, ranking in the top 75% percentile for APP store conversions within the social media category—a remarkable feat for a recently launched application. Building on the success of industry giants like Facebook (NASDAQ: META)Snapchat (NYSE: SNAP) and TikTok that harnessed the power of community engagement to achieve explosive growth, GolfLync's visionary founders quickly trademarked Virtual Golf Clubs(TM) ("VGC"), swiftly expanding its features. With VGC, members are able to discover local golf communities and public clubs, finding like-minded individuals who share their passion for the sport. Fueled with an intelligent algorithm, the platform offers a personalized experience, connecting golfers based on location, interests and proficiency, including handicap and playing preferences.

To view the full press release, visit https://ibn.fm/BkfI1

GolfLync Inc. matches golfers looking for a game through the company’s smartphone app, GolfLync. The company bills GolfLync as “the social network for golfers,” matching golf games and players similar to the way a dating app matches those looking for romance.

The app allows like-minded golfers to connect for a game simply by logging in. GolfLync helps golfers who are looking to grow their golf network find other players with similar interests and on course preferences. Whether you have recently moved to a new area and are looking for new golfing buddies, travel frequently and would like to play a round of golf while on the road, or just want to meet new golfers in your area, GolfLync is your answer. Spouses who enjoy golfing together can find other golfing couples to tee it up with. For a regular group that finds itself unexpectedly down a player, GolfLync can help find that last-minute addition to complete the foursome.

The company is based in Scottsdale, Arizona.

GolfLync App

GolfLync was created for golfers of all skill levels and preferences to connect with compatible players of similar skill. Golfers can find a tee time through GolfLync, join existing tee times and create new leagues. The app allows golfers to meet fellow players before committing to spend four hours on the course with them. GolfLync allows users to find new golf friends based on their preferences, such as walking or riding a cart, listening to music, friendly wagering, imbibing a favorite beverage at the 19th Hole and more. GolfLync is available for both Android and iOS as a free download.

Download on Apple App Store   Get it on Google Play

Market Opportunity

According to a report by Statista, a leading provider of market and consumer data, in 2022, the number of people participating in golf in the United States reached 25.6 million, with 15.5 million additional players participating in off-course activities like driving ranges. In 2020, over 502 million rounds of golf were played in the U.S. alone. The game, traditionally dominated by male players, is changing, with increased interest from women golfers driven by social media influencers around the game.

Lumen Sports puts the total number of golf courses in the U.S. at more than 16,700. According to Lumen, about 75% of those are public courses open to all golfers, with the rest considered private golf clubs that require a membership.

 

Management Team

Noah DiPasquale is a co-founder and CEO of GolfLync Inc., leading the marketing and operations of the platform. He is also the founder and CEO of Epic Golf Club, a premier national membership and private golf society which partners with hundreds of top tier private golf clubs allowing Epic members access to their courses and recently founded the Epic Foundation, a Scottsdale-based 501c3. He holds a B.S. in Business Administration, Management and Operations from the W.A. Franke College of Business at Northern Arizona University and an MBA in Marketing from the University of Phoenix.

Michael Quiel is a co-founder of GolfLync Inc. and the President of the organization. He leads the application development and research teams. Michael understands how to build successful companies. His deep knowledge of investment banking, finance and building successful business partnerships is unparalleled. He’s an expert at capital formation and growth hacking companies. He has raised over $250 million in capital and taken multiple companies public.

Recent News

chart

NextPlat Corp. (NASDAQ: NXPL) (NASDAQ: NXPLW)

The QualityStocks Daily Newsletter would like to spotlight NextPlat Corp. (NASDAQ: NXPL) (NASDAQ: NXPLW).

Data on consumer behavior trends show that people are increasingly gravitating toward making e-commerce purchases on mobile apps. Last year, 39% of internet users in America made at least one weekly mobile purchase via e-commerce apps, indicating the consumer need for quick and frictionless transactions. E-commerce became one of the most dominant forms of trade long before mobile phones became easily accessible, but it is becoming increasingly reliant on mobile phones for traffic. By the end of 2022, there were an estimated 4.32 billion active mobile internet users in the world, an extremely large market of consumers for any online retailer to tap into. Most consumers prefer to browse the internet on their mobile phones, and retailers can leverage this trend by investing in customized e-commerce apps. Enterprises such as NextPlat Corp. (NASDAQ: NXPL) (NASDAQ: NXPL) are helping to apply these practices within the healthcare e-commerce space, and traffic is likely to grow as time passes.

NextPlat Corp. (NASDAQ: NXPL) (NASDAQ: NXPLW), a next generation e-commerce platform, was created with vision and purpose to capitalize on high growth sectors and global markets. The company collaborates with businesses – large and small – to simplify and accelerate online commerce and uniquely enables customers and partners to optimize their e-commerce reach, presence and revenue. NextPlat recently launched a new e-commerce development program to provide American businesses with easy access to the massive Chinese consumer market.

Current Initiatives

NextPlat provides cutting edge technology in an advanced e-commerce ecosystem. The company is actively expanding its global network of online storefronts serving thousands of consumers, enterprises and governments. The company also has developed a next generation platform built for Web3 that enables the creation and sale of digital assets, as well as optimizing e-commerce transactions and business building activities. The company’s current initiatives include:

  • E-Commerce Development Program – In April 2023, NextPlat announced it had entered into a merchant sourcing agreement with Alibaba.com Singapore E-Commerce Private Limited (“Alibaba”) and its Tmall Global e-commerce platform whereby the two companies will collaborate to increase the sale of products produced and sold by American companies to the multi-trillion-dollar Chinese consumer market. Alibaba’s Tmall Global e-commerce platform will provide NextPlat customers a turn-key solution through which products can be sold to the Chinese consumer market. The launch of the Florida E-Commerce Development Program is the first in a series of new NextPlat programs designed to assist U.S. businesses in expanding their online sales capabilities to reach new international customers in the Chinese market. NextPlat intends to rapidly expand this unique e-commerce development opportunity to businesses throughout the United States and all of North America, as well as Central and South America. The new development program features NextPlat’s turnkey global e-commerce solution for customers and leverages NextPlat’s relationships with key partners, including Tmall Global, China’s largest cross-border B2C online marketplace.
  • Progressive Care Inc. – In August 2022, NextPlat completed a strategic $7 million investment in Progressive Care Inc. (OTCQB: RXMD), a personalized health care services and technology company. In a news release announcing the investment, NextPlat CEO Charles M. Fernandez noted that the company is “committed to harnessing the power of digital technologies to capitalize on the ongoing digital transformation of Progressive Care and the entire health care industry.” NextPlat intends to accelerate Progressive Care’s digital health care transformation with the launch of a new e-commerce platform for health care products later this year.
  • NextPlat NFT Platform – Building on its existing e-commerce initiatives, NextPlat is working to bridge the gap between tangible and digital e-commerce marketplaces by incorporating burgeoning Web3 technologies. The company intends to launch a fully integrated NFT platform in the coming months that will enable brands to create, manage and authenticate digital assets while serving as a new source of revenue for NextPlat. Through this model, the company will receive a portion of the revenue generated from branded NFT drops, as well as subsequent secondary market transactions.
  • Global Telesat Communications and Orbital SatCom Corp. – Targeting both domestic and international markets, NextPlat’s subsidiaries leverage partnerships with major e-commerce platforms such as Amazon, Alibaba, eBay and Walmart to serve a growing base that includes more than 50,000 corporate, governmental and individual customers. In total, the brands market more than 10,000 individual products, with a focus on satellite-based connectivity solutions. In addition to exploring accretive M&A opportunities, NextPlat aims to diversify its range of products and broaden its geographic footprint moving forward in an effort to better capitalize on the tremendous growth potential in the United States, Europe and Asia.

“Our goal for 2023 and beyond is to leverage our improved operational capabilities and enhanced leadership team as we expand our offerings in communications and connectivity into the high-growth health care market where we intend to launch an array of innovative new offerings,” Fernandez said in a March 2023 news release detailing the company’s record top-line performance. “Although there remain supply chain headwinds and the challenge of global inflation, we are confident that we have the right combination of market-tested expertise, technology and partnerships that will enable us to bring the power of e-commerce to more customers, brands and industries in the United States and abroad.”

Market Opportunity

The rapid growth of e-commerce over the last decade is expected to continue for the foreseeable future. According to data published by Forbes, roughly 20.8% of all retail purchases are expected to take place online in 2023, accounting for total sales of $6.31 trillion worldwide. It total, e-commerce sales are expected to grow by 10.4% YoY in 2023, accounting for a whopping 24% of all retail purchases by 2026.

For NextPlat, existing partnerships in the industry could be key to capitalizing on this growth. The Forbes report indicates that Amazon accounts for roughly 38.7% of e-commerce sales, while sites like Walmart, eBay and Alibaba round out the list of most visited e-commerce websites. Alibaba is especially interesting due to NextPlat’s recent strategic merchant sourcing agreement with Tmall Global. The Chinese market is “mammoth,” as a recent Alizila report noted. The country’s annual online retail sales of physical goods have nearly doubled in the last five years, reaching approximately 13.8 trillion yuan in 2022, which is nearly $2 trillion USD.

The health care portion of the e-commerce market is generating particularly bullish forecasts, bolstered by the continued adoption of the 340B Drug Pricing Program in the U.S., which requires most drug manufacturers to provide outpatient drugs to covered entities at significantly reduced prices. Industry reports suggest that the global health care e-commerce market will expand at a compound annual growth rate of 16.8% from 2022 to 2030, climbing to a value of more than $1.37 trillion by the end of the forecast period.

Management Team

Charles M. Fernandez, CEO, Executive Chairman and Director of NextPlat, has over three decades of experience in identifying profitable start-up and dislocation opportunities, building significant value and executing exit strategies as an entrepreneur and global investor. Successful across multiple sectors, Fortune Magazine actually labeled Fernandez ‘a restructuring whiz’. As President of Fairholme Capital Management, which he joined in 2008, Mr. Fernandez co-managed all three Fairholme funds and brought in a $2 billion gain for shareholders. Throughout his impressive career, he has participated in more than 100 significant mergers, acquisitions and product development projects across multiple industries. Mr. Fernandez was the founder, Chairman and CEO of eApeiron Solutions LLC, a brand protection and e-commerce company in partnership with Alibaba (NYSE: BABA) and Eastman Kodak (NYSE: KODK), which was successfully sold to Smartrac, a unit of Avery Dennison Corp. (NYSE: AVY).

Rodney Barreto is Chairman and CEO of the Barreto Group and Director of Nextplat. Mr. Barreto’s business career spans over 35 years, including his role at the Barreto Group and, earlier, as the founding partner of Floridian Partners LLC, a corporate and public affairs consulting firm recognized by policy makers as one of the top in its industry in Florida. He chaired the Super Bowl Host Committee in 2007, 2010 and 2020, helping to raise more than $100 million for the success of Miami Super Bowls. As a philanthropist and conservationist, Mr. Barreto is also a three-time appointee to the Florida Fish and Wildlife Conservation Commission, where he has served for over 10 years including holding the title of Chairman eight times. He has twice chaired the Annual U.S. Conference of Mayors, was Chairman of the 1999 Breeder’s Cup Championship held in South Florida and was the Chairman of the 1999 Sister Cities International Convention in Miami. Currently, Mr. Barreto is the Membership Chairman of the Florida Council of 100, and a member of the Boards of Fairchild Tropical Botanic Garden, the Baptist Health South Florida Giving Society, the Bonefish and Tarpon Trust, the Guy Harvey Ocean Foundation, and a member of Miami Dade County Schools Superintendent Carvalho’s Business Advisory Council. Prior to his career in public affairs and real estate, Mr. Barreto was a City of Miami police officer and is a member of the Florida Highway Patrol Advisory Council.

NextPlat Corp. (NXPL), closed Tuesday's trading session at $2.81, off by 1.0563%, on 1,408 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $1.2115/$4.26.

Recent News

Canada Nickel Company Inc. (TSX.V: CNC) (OTCQX: CNIKF)

The QualityStocks Daily Newsletter would like to spotlight Canada Nickel Company Inc. (TSX.V: CNC) (OTCQX: CNIKF).

The company behind a massive industrial mine in Indonesia that is swiftly becoming a major nickel producer says that it is implementing policies to address the environmental concerns associated with mining nickel.

Nickel is among a group of minerals used to develop the rechargeable batteries in everything from mobile phones and laptops to electric vehicles and stationary storage solutions. As major economies such as the United States, China and countries in the European Union transition from dirty fuels and gas-powered cars to electric vehicles and renewable energy, demand for metals such as nickel are expected to skyrocket.

Last year, Brazilian mining company Vale said that it expects to see a 44% increase in worldwide nickel demand by the end of the decade. However, with global nickel production expected to scale up to meet the growing demand, there have been growing concerns about the environmental impact of expanding nickel mining operations. As more major mineral extractors such as Canada Nickel Company Inc. (TSX.V: CNC) (OTCQX: CNIKF) follow this example and put ecofriendliness at the core of their operations, the perception of nickel mining as an environmentally harmful process will fade with time.

Canada Nickel Company Inc. (TSX.V: CNC) (OTCQX: CNIKF) is advancing the next generation of nickel-cobalt sulfide projects to deliver the metals needed to power the electric vehicle (EV) revolution and feed the high growth stainless steel market. The company is one of only a few new sources of potential supply outside Indonesia and China.

Canada Nickel possesses industry leading nickel expertise and is focused on low risk, well established mining jurisdictions. The company has launched wholly owned subsidiary NetZero Metals Inc. to develop zero-carbon production of nickel, cobalt and iron and has applied in multiple jurisdictions to trademark the terms NetZero Nickel, NetZero Cobalt and NetZero Iron. Canada Nickel is also pursuing development of processes to allow net zero carbon production of these elements.

Canada Nickel is currently anchored by its 100% owned flagship Crawford Nickel-Cobalt Sulfide Project with large-scale potential located in the heart of Ontario’s prolific Timmins-Cochrane mining camp, adjacent to major infrastructure.

The company believes the EV industry and many other consumer sectors have an urgent need for zero-carbon metal this decade, not in 20-25 years as contemplated by some resource companies. Canada Nickel also believes that nickel supplies from Indonesia and other Pacific island nations, typically controlled by Chinese-owned companies, are not the answer for batteries needed by GM, Ford and the European automakers working to develop and manufacture EV models.

The company is headquartered in Toronto.

Crawford Nickel-Cobalt Sulfide Project

The Crawford Nickel-Cobalt Sulfide Project is the largest sulfide discovery since the early 1970s and contains the fifth-largest nickel sulfide resource in the world, based on Measured & Indicated resources, according to the latest update. The Crawford project is expected to be one of the largest base metal mines in Canada based on results of a Preliminary Economic Assessment. Early projections by Canada Nickel estimate that the project has the potential to produce 50,000 tons of nickel per year. The company is now in the final stages of completing the project’s feasibility study.

The project is projected to produce 2.8 tons of CO2 per ton of nickel equivalent production, which is 89% lower than the industry average of 34 tons of CO2 per ton of nickel equivalent production.

The company is taking significant steps toward developing the Crawford project as a net zero carbon producer. In addition to harnessing the natural ability of the project’s geology to act as a carbon sink through spontaneous reaction of the host rock once exposed to atmospheric conditions called mineral carbonation, Canada Nickel has discovered a new way to enhance carbon capture, termed In Process Tailings (IPT) Carbonation. This act of conditioning the tailings with a concentrated stream of carbon dioxide before deposition has been demonstrated at lab scale to achieve carbon capture at a rate 8-12 times faster than naturally occurring sequestration, achieving more than 60% of the capture that had previously taken six days.

These latest results move the company further toward production of Net Zero Nickel™ and generation of 21 tonnes of CO2 credits per tonne of nickel, which would produce an estimated average of 710,000 tonnes of CO2 credits annually and 18 million total tonnes of CO2 credits over the expected life of mine. IPT Carbonation does not require complex new technologies and major process modifications and could encourage the development of a net zero carbon industrial cluster centered around the Crawford project.

Canada Nickel in January 2023 announced that its latest test work results support the incorporation of carbon capture and storage into the Crawford project. The company believes that utilization of existing process streams should allow IPT to be efficiently engineered and incorporated into the project’s flowsheet, with an integrated feasibility study for the project expected in the second quarter of 2023.

In December 2022, Canada Nickel announced its engagement on Deutsche Bank Securities Inc. (“Deutsche Bank”) and Scotiabank – two of the world’s leading investment banks with a broad base of mining and industrial expertise – as financial advisors for the equity component of the project financing for the Crawford project. In the same release, the company announced the completion of another significant permitting milestone by filing the detailed project description with the Impact Assessment Agency of Canada. Canada Nickel targets receipt of permits by mid-2025, with construction to immediately follow.

Additional Projects

The Reid Nickel Property is located just 16 kilometers southwest of Crawford, or 37 kilometers northwest of Timmins, and contains an ultramafic body with a target geophysical footprint of 3.9 square kilometers. Preliminary assay results from Canada Nickel’s summer/fall drilling program confirm the presence of mineralized dunite, as well as currently undefined higher-grade sections. Partial assay results confirm expected nickel grades. Nickel mineralization in serpentinized dunite was found in all 16 holes drilled to date.

The Sothman Nickel Property is located 70 kilometers south of Timmins. Five drill holes on the eastern half of the target anomaly confirmed the continuation of ultramafic lithologies, primarily peridotite, with moderate to strong serpentinization and variable amounts of mineralization throughout.

The company in December 2022 announced positive drilling results from its ongoing regional exploration campaign at its Reid and Sothman properties. These latest results continue to reinforce the success of Canada Nickel’s geophysical targeting approach and increase the probability of success at the company’s other 20-plus properties within its 42 square kilometers of geophysical targets.

Building on this momentum, Canada Nickel in December 2022 announced its entry into a deal to acquire a 100% interest in the past producing Texmont property situated between the company’s properties south of Timmins. As noted in the news release, the acquisition of the Texmont property provides near-term smaller scale production potential and is highly complementary to the company’s large-scale Crawford and regional nickel sulphide projects.

Market Opportunity

Global demand leaves the market fundamentally short of nickel in the medium- and long-term. Global primary nickel demand will likely reach 3 million tons in 2022, up from 2.4 million tons in 2020, according to the International Nickel Study Group (INSG).

The INSG says primary nickel production is forecast to hit 3.1 million tons in 2022. Indonesia, the world’s largest nickel miner, halted exports of unprocessed nickel ore in January 2020, due to a government-imposed ban. Indonesia has floated the concept of a nickel cartel whose member nations would exert influence over world nickel supply and prices, similar to OPEC’s pricing power over oil.

Benchmark Minerals, a leading EV supply chain research firm, projects that, by 2035, world demand for nickel will double from current levels to 6 million tons annually. That growing demand represents a need for new nickel production equivalent to 70 mines the size of Canada Nickel’s Crawford Project.

Management Team

Mark Selby is Chairman, CEO and Director of Canada Nickel. He was formerly President and CEO of RNC Minerals, where he led a team that successfully raised over $100 million and advanced the Dumont nickel-cobalt project from initial resource to a fully permitted, construction-ready project. He has held senior management roles with Quadra Mining, Inco and Purolator Courier, and was a partner at Mercer Management Consulting. Since 2001, he has been recognized as one of the leading authorities on the nickel market. He graduated from Queen’s University with a Bachelor of Commerce.

Wendy Kaufman is CFO of Canada Nickel. She has 25 years of experience leading publicly listed mining companies in project financing, capital structuring, capital markets, accounting and internal controls, tax, and financial reporting and public disclosure. She was also previously CFO at Khiron Life Sciences Corp. and held CFO and senior finance positions at Pasinex Resources Limited, Primero Mining Corporation and Inmet Mining Corporation. She holds a Bachelor of Business Administration from Wilfrid Laurier University and is a Chartered Professional Accountant.

Steve Balch is VP Exploration at Canada Nickel. He is an Ontario registered geoscientist with 32 years of experience in geophysics, specializing in magnetic and electromagnetic methods. He founded Triumph Instruments and developed the AirTEM system, a multi-coil helicopter-borne EM system that is in use worldwide. He has also been active in borehole geophysics and helped develop new technologies including north-seeking gyros, temperature compensated induction conductivity probes, UAV-based magnetometers and high sensitivity magnetic gradiometers.

Christian Brousseau is VP Capital Projects at Canada Nickel. He is a professional engineer (P.Eng) with over 30 years of experience in engineering, design and construction in the Canadian mining industry, including six years as Project Director for the Dumont Project and three years as the Engineering and Construction Manager for Detour Gold. Prior to Detour, he held various construction management positions at Osisko’s Malartic Project and at Goldcorp’s Éléonore Project. He also spent eight years at Falconbridge supervising and managing various capital projects.

Canada Nickel Company Inc. (OTCQX: CNIKF), closed Monday's trading session at $2.05, up 3.0151%, on 73,251 volume with 375 trades. The average volume for the last 3 months is 57,207 and the stock's 52-week low/high is $1.04999995/$5.63000011.

Recent News

CISO Global, Inc. (NASDAQ: CISO)

The QualityStocks Daily Newsletter would like to spotlight CISO Global, Inc. (NASDAQ: CISO).

CISO Global Inc. (NASDAQ: CISO), has unveiled Argo Edge, a powerful tool stack the company has been developing and testing for the past two years. According to the announcement, Argo Edge combines the most sought-after security technologies available with CISO's proprietary IP and threat feeds to provide a prebuilt, easy-to-implement solution created for use by both government and privately held entities. The new AI-powered security solution, which has been independently valued at $49 million, enhances cybersecurity effectiveness through coordination, integration and automation. The company stated that Argo Edge layers together preconfigured, preintegrated technologies that include cloud firewall as a service ("FaaS"), secure internet gateway, secure authentication, secure service edge ("SSE") and containerized internet browser sessions for each user. Argo Edge also provides Zero Trust Network Access ("ZTNA"), Cloud Access Security Broker ("CASB") and Data Loss Protection ("DLP") capabilities along with overall improved network performance.

"We believe this valuation solidifies CISO Global as a growing leader in the cybersecurity industry, and that the solution's capabilities validate the company's ability to deliver on its mission to demystify and accelerate its clients' journey to cyber resilience," said CISO Global CEO David Jemmett in the press release. "Unlike most security platforms currently on the market that add complexity and increase the need for additional staff to manage them, Argo Edge leverages automation and preconfigures highly complex security processes."

To view the full press release, visit https://ibn.fm/Ui8jE

CISO Global, Inc. (NASDAQ: CISO) is an industry leader in cybersecurity and compliance services. The company leverages an integrated approach to reduce noise and bridge common silos that often limit the effectiveness of cybersecurity programs. Pulling disparate technologies, teams, and vendors together, CISO helps its clients enjoy a simpler and more successful journey to cyber resilience. Since 2019, CISO Global has worked to rapidly expand by acquiring world-class cybersecurity and compliance businesses with top-tier talent who utilize the latest technology to create innovative protection solutions.

The CISO Global workforce is comprised of cybersecurity experts spanning not only global geographies, but also specialties, industries, regulatory frameworks and focus areas. Its team includes audit and compliance specialists, certified forensics experts, ethical hackers, IEEE® certified biometric professionals, security engineers, around-the-clock analysts, and more – all backed by the most respected credentials in the industry. On an ongoing basis, the company works to identify cyber talent that is culturally aligned and that offers operating leverage through both existing customer revenue and relationships.

CISO Global has invested in enterprise solutions and executive talent to integrate its different organizations into an ecosystem that works together to provide complete cybersecurity through cross-pollination of solutions that begin at the network level and extend through technologies, people, policy, and practices. This ecosystem is intended to foster additional growth opportunities and drive overall recurring revenue. Once engaged, the company strives to become trusted advisors for customers’ cybersecurity and compliance demands by providing tailored security solutions based upon their organizational needs.

While cyber resilience requires cycles of continuous improvement, it is a journey that few in the current business and security climate seem to understand. With its deep bench of seasoned experts, CISO Global works to simplify that journey for its growing customer base, straightening out the curves and speeding up the process to resilience along the way.

Cybersecurity is a Culture, Not a Product

Integrating compliance and security, including principles of security by design, CISO Global helps its clients create an organization-wide culture of cybersecurity. Its offerings include audit and compliance, security operations center services, security engineering, virtual Chief Information Security Officer services, incident response, certified forensics, technical assessments and cybersecurity training.

In contrast to the majority of cybersecurity firms that specialize in a specific technology or service, CISO Global seeks to differentiate itself by remaining technology agnostic, focusing on accumulating highly sought-after subject matter experts. CISO Global believes that bringing together a world-class team of technological experts with multi-faceted proficiency in the critical aspects of cybersecurity is key to providing technology agnostic solutions to its clients in a business ecosystem that suffers from a chronic lack of highly skilled professionals.

CISO Global’s goal is to create a culture of security and to help quantify, define and capture a return on investment from information technology and cybersecurity spending. Its end-to-end, holistic process covers every aspect of clients’ cybersecurity and compliance requirements in an effort to promote greater efficiency and strengthen awareness about the integral role of internal team members in the cybersecurity culture of an organization.

As a result of this strategy, CISO Global customers receive an efficient engagement from a single partner that covers a wide range of their needs – addressing challenges more thoroughly and resolving problems more rapidly when compared to working with a host of vendors.

Market Outlook

According to an analysis by the firm Research and Markets, the global managed security services market was valued at $22.45 billion in 2020 and is projected to reach $77.01 billion by 2030, growing at a CAGR of 12.8% through the forecast period.

An expected increase in cybercrime, cost effectiveness of provided solutions and stringent mandatory government regulations aimed at protecting corporate data will drive the global managed security services market for the foreseeable future.

In addition, the documented and growing use of mobile devices in the workplace and the rise in captured and stored digital data serve to fuel market growth. Moreover, growing awareness about the critical nature of data security, the growing importance of e-business and demand for customized services is expected to offer ample opportunities for expansion of the market during the forecast period.

Management Team

David Jemmett is CEO and founder of CISO Global. He has more than 35 years of executive management and technology experience with telecommunications, managed services, and cybersecurity consulting services. He previously held positions as CEO of GenResults, a leading provider of security consulting services and technology solutions, and as CTO and founder at ClearData Networks, a HIPAA-compliant HealthDATA cloud hosting platform.

Dave Bennett is COO at CISO Global. Since 2015, he has served on the President’s STEM Advisory Board of Grand Canyon University. Before joining CISO Global, he served as Chief Product Officer at Experian Health and as Senior Vice President, Product for Gainwell Technologies. He has also held positions as Vice President and Worldwide Head of Build, Healthcare and Life Sciences at DXC Technology, and as EVP, Product and Strategy at Orion Health.

Ashley Devoto is President and Chief Information Security Officer at CISO Global. Over the past 17 years, Devoto has worked with the cybersecurity elite to design, build, and operate world-class cybersecurity programs for large, diverse organizations in both government and commercial enterprises. Prior to joining CISO, Devoto served as CISO for Booz Allen Hamilton, as business information security officer (BISO) at Bank of America, and as a cyberspace operations officer in the United States Air Force.

Deb Smith is CFO at CISO Global. Prior to assuming that position, she was the company’s EVP, Finance and Accounting. She has also served as SVP, Global Accounting at International Cruise and Excursions Inc., and as Chief Accounting Officer for BeyondTrust, an information security software company. She has also held the positions of Corporate Controller at Aspect Software and Assistant Controller at JDA Software.

CISO Global, Inc. (NASDAQ: CISO), closed Monday's trading session at $2.05, up 3.0151%, on 73,251 volume with 375 trades. The average volume for the last 3 months is 57,207 and the stock's 52-week low/high is $1.04999995/$5.63000011.

Recent News

Mullen Automotive Inc. (NASDAQ: MULN)

The QualityStocks Daily Newsletter would like to spotlight Mullen Automotive Inc. (MULN).

Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle ("EV") manufacturer, has announced a 1 for 9 reverse split. According to the announcement, the company plans to repurchase up to $25 million in shares through a stock buyback program after the filing of its 10-Q and upon expiration of its blackout period. In making the announcement, the company noted NASDAQ Listing Rule 5810(c)(3)(H), which states that "if a Company fails to meet the [Minimum Bid Price requirement], compliance is generally achieved by meeting the requirement for a minimum of ten consecutive business days. However, Staff may, in its discretion, require a Company to [maintain a bid price of at least $1.00 per share] for a period in excess of ten consecutive business days, but generally no more than 20 consecutive business days, before determining that the Company has demonstrated an ability to maintain long-term compliance. In determining whether to require a Company to meet the [minimum $1.00 bid price standard] beyond ten business days, Staff will consider the following four factors: (i) margin of compliance (the amount by which the [bid price is above the $1.00 minimum standard]); (ii) trading volume (a lack of trading volume may indicate a lack of bona fide market interest in the security at the posted bid price); (iii) the Market Maker montage (the number of Market Makers quoting at or above $1.00 and the size of their quotes); and, (iv) the trend of the stock price (is it up or down)." In the press release, Mullen Automotive CEO and chair David Michery stated: "We believe the company is highly undervalued, and the stock buyback program represents a compelling use of our capital, reflecting confidence in our business."

To view the full press release, visit https://ibn.fm/nS9EL

Mullen Automotive Inc. (NASDAQ: MULN) is a Southern California-based automotive company that owns and partners with several synergistic businesses working toward the unified goal of creating clean and scalable energy solutions. Mullen has evolved over the past decade in sync with consumers and technology trends. Today, the company is working diligently to provide exciting EV options built entirely in the United States and made to fit perfectly into the American consumer’s life. Mullen strives to make EVs more accessible than ever by building an end-to-end ecosystem that takes care of all aspects of EV ownership.

Commencement of Trading on Nasdaq

On November 5, 2021, Mullen announced its commencement of trading on the Nasdaq Capital Market.

“Today is a monumental day for Mullen Automotive. I am especially proud of our team, investors and all who have believed in Mullen and taken us to this point as a publicly traded company on the Nasdaq Capital Market,” David Michery, CEO and Chairman of Mullen Automotive, stated in the news release. “Trading on Nasdaq now opens us up to new investors, both institutional and retail shareholders, and broadens our awareness and company profile, while increasing awareness of Mullen and our technology platform and opening new opportunities in EV and beyond. The road ahead has never been brighter for Mullen, and I am proud to lead us into the future.”

The milestone came in the wake of the company’s stock-for-stock merger with Net Element Inc.

The Mullen FIVE

The Mullen FIVE EV Crossover, debuting at the Los Angeles International Auto Show (LAIAS) on November 17, 2021, embodies Mullen’s Southern California roots with an inspired design focused on two complementary Golden State themes – California landscape and California urban.

The FIVE is built on an EV Crossover skateboard platform that offers multiple powertrain configurations and trim levels in a svelte design that is Strikingly Different™ and exciting to experience in person.

Prior to the start of LAIAS, the Mullen FIVE was selected as a finalist by the LA Auto Show for Top EV SUV in the ZEVA “People’s Choice” Awards.

LAIAS provides Mullen an opportunity to display multiple variants of the FIVE model while also showcasing its powertrain, battery and charging technology. The company intends to bring the FIVE to market in 2024, and reservations are currently open here.

Mullen’s development portfolio also includes EV Fleet Vans, which it intends to bring to market in Q2 2022, and the pure electric, high performance Mullen DragonFLY.

Expansion of Manufacturing Capacity

On November 2, 2021, Mullen announced plans to expand its facility in Robinsonville, Mississippi.

Mullen’s Advanced Manufacturing and Engineering Facility (AMEC) currently occupies 124,000 square feet of manufacturing space. The total available land on the property is over 100 acres, and Mullen is moving ahead with plans to build out another 1.2 million square feet of manufacturing space to support class 1 and class 2 EV cargo vans and the Mullen FIVE EV Crossover.

On the expanded site, Mullen plans to build a body shop, a fully automated paint shop and a general assembly shop.

EV Market Outlook

The global EV market was reported to consist of 3,269,671 units in 2019, a figure that is expected to grow at a CAGR of 21.1% through 2030 to a total of 26,951,318 units worldwide. This market’s monetary value was estimated at $162.34 billion in 2019 and is expected to grow at a CAGR of 22.6%, resulting in an approximate value of $802.81 billion by 2027. The primary driver for this exponential growth is a worldwide increase in vehicle emissions regulations.

Management Team

David Michery is the CEO and Founder of Mullen and has been leading the company and its divisions since inception in 2014. With over 25 years of executive management, marketing, distressed assets, and business restructuring experience, Mr. Michery brings a wealth of relevant knowledge and expertise to the Mullen brand. He has notably created 12 trademarks so far to develop the company brand and vision.

Mr. Michery is working toward a sustainable future accessible to all by creating a suite of clean-energy electric vehicles at varied price points. With entirely U.S.-based manufacturing and operations, he is also determined to have Mullen Technologies play a role in shaping a self-sustaining local economy by creating more jobs in America.

Mr. Michery manages risks and company expectations as a pathway to success and has personally overseen several businesses that totaled over $1 billion in transactions. His key strength is the ability to be fiscally responsible and lead teams to complete projects on time and within budget. As a seasoned professional in this space, Mr. Michery has demonstrated skill in building businesses from the ground up and into successful entities that subsequently sold for hundreds of millions of dollars.

Mullen Automotive Inc. (MULN), closed Tuesday's trading session at $0.1126, off by 0.880282%, on 320,907,802 volume. The average volume for the last 3 months is 314.429M and the stock's 52-week low/high is $0.10/$23.25.

Recent News

Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF)

The QualityStocks Daily Newsletter would like to spotlight Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF).

Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) is the leading psychedelic wellness platform, committed to bringing science-backed benefits to all and reframing the psychedelic conversation. The company owns and operates an umbrella of related businesses, including trusted media and e-commerce platforms like Reality Sandwich and Delic Radio; Delic Labs, the only licensed entity by Health Canada to exclusively focus on research and development of psilocybin vaporization technology; Meet Delic, the premiere psychedelic wellness event; and Ketamine Infusion Centers, one of the largest ketamine clinics in the country.

Delic is backed by a team of industry and cannabis veterans and a diverse network, whose mission is to provide education, research, high-quality products, and treatment options to the masses. Its founders helped build the multi-billion-dollar cannabis industry and aim to do the same in psychedelics as it follows a similar path toward legalization. In its quest to advance the new psychedelic renaissance upon us, Delic has become the pioneer in its field, creating an ecosystem of opportunities by investing in cutting-edge ideas.

The Vancouver-based company was formed in 2019 to address the growing interest in psychedelic wellness backed by science. Delic was the ‎first psychedelic umbrella platform. It is currently a trusted source for those interested in ‎psychedelic culture, education, treatments, and more.

While other emerging companies focus on patent medicine and big pharma for substances limited by government regulation, Delic is blazing a unique trail. It identifies ancillary and fully legal opportunities like IP, new media, live events, ketamine clinics (with the ability to offer additional psychedelic treatments once legalized, and large-scale production and brings them under its big tent of resources and reach.

The Big Problems Delic Is Addressing

  • Fifty percent of Americans will meet the criteria for a mental health condition sometime in their lifetime. The FDA has approved psilocybin therapy as a breakthrough therapy for depression.
  • Every 40 seconds, someone in the world commits suicide. Ketamine has been shown to decrease thoughts of suicide significantly. In 2019, the FDA approved esketamine as a fast-acting antidepressant.
  • Traditional palliative care methods do not eradicate end-of-life (EOL) anxiety. LSD and psilocybin have been shown to reduce EOL anxiety for terminally ill patients. Eighty percent of terminally ill patients with psilocybin sessions experienced significant reductions in depression and anxiety.
  • Approximately 50 million people in the U.S. are addicted to some tobacco product. Research shows that psilocybin is helping people quit smoking.

The Delic Ecosystem

The Delic Ecosystem covers three main areas: media, health, and science. The media focus is educating and motivating the masses through a variety of digital platforms, like Delic’s Reality Sandwich digital magazine, a free public education platform providing psychedelic guides, news and ‎culture (1.4+ million page views in 2020 and 54k social media followers across all platforms); Meet Delic, the first-ever psychedelic wellness summit and the premier psychedelic wellness event based in Las Vegas (over 2,000 live attendees and 5,000+ email subscribers); and Delic Radio (over 43 episodes and 100k total streams). Delic has also been featured in numerous media outlets like Forbes, NBC News, The Joe Rogan Experience, Daily Beast, High Times, and The Dr. Drew Podcast.

The focus of Delic’s health operations is the most accessible psychedelic treatments that can help billions of people live happier lives. Delic does this through one of the largest ketamine clinic chains in the country, Ketamine Infusion Centers (KICs), a limited liability corporation formed under the laws of Arizona that runs three ketamine clinics located in Bakersfield, California, and Phoenix, Arizona. Its management team has over 15 years of experience in the clinic and medical space, scaling and operating over 20 clinics, with a plan to open 10 more clinics in the next 18 months. Together, these clinics have overseen 4,000+ treatments delivered to date.

The focus of Delic’s science operations is developing IP and advanced extraction and testing facilities that are the backbone of the legal market. Delic carries this out through Delic Labs, a licensed cannabis and psilocybin research laboratory based in Vancouver. It’s the only entity licensed by Health Canada to exclusively focus on research and development of psilocybin vaporization technology.

Founded by award-winning chemists, Delic Labs focuses on extraction optimization, analytical testing, and chemical process development to advance the cannabis and psilocybin industries. Health Canada gave it a Section 56 Exemption to work with psilocybin compounds, allowing the company to possess and research these products for development and quality control before they hit the market.

Latest Acquisition – Homestead Book Company

On March 4, 2021, Delic announced its acquisition of Seattle-based Homestead Book Company. Homestead is a legacy counterculture distributor of psychedelic media. It’s also the creator of one of the first self-contained psilocybin mushroom grow kits.

The acquisition of Homestead is an exciting one, as it shows how Delic is increasing accessibility to this nascent industry within regulated jurisdictions. Homestead has sold tens of thousands of mushroom kits globally and was one of the earliest distributors for High Times and many other counterculture publications.

The Homestead acquisition allows Delic to increase its product offerings on its website, Reality Sandwich, which recently hit a record for average monthly traffic of over 200,000 unique visitors and over 2.6 million active readers in 2020.

Market Outlook

The psychedelic renaissance is here. Just in time to help address the global mental health crises, plant medicines have the potential to help billions of people live happier lives. Thanks to university-led and FDA-approved studies, North America is leading the way in advancing an industry as psychedelics are becoming accepted globally for therapeutic, medical, and recreational use. Here are some statistics:

  • 32 million people in the U.S. have used psychedelics at least once
  • 17% of all American adults between 21 and 64 have used psychedelics at least once
  • $500 billion is spent in the U.S. every year on prescription drugs
  • $238 billion is spent in the U.S. every year on mental health treatments and ancillary services
  • The anxiety disorder and depression treatment market is estimated at $16 billion
  • $187.8 billion was spent in 2013 on mental health and substance abuse disorders

Management Team

Delic Co-Founder and CCO Jackee Stang was an executive at High Times, a leading counterculture publication that became the voice for the cannabis industry. The monthly magazine had a circulation of over 500,000 copies per issue. Its website attracted 500,000 to five million users each month by 2014.

Likewise, company Co-Founder and CEO Matt Stang was a previous owner and operator of High Times, a position from which he played an instrumental in legalizing cannabis in multiple states and launched the Cannabis Cup in America. After interacting with the cannabis community for two decades, he helped found Delic in 2019 as one of the first psychedelic corporations. He shapes the company’s vision and path using his expertise in branding, marketing, business development, and product viability.

Delic’s VP of Business Development, John Coleman, Ph.D., is a former president of Anandia Labs, a biotech company focused on genetics and analytics. Having experience in both science and business, Dr. Coleman is well-equipped to lead Delic’s business development efforts as it strives to enter new vertical markets.

Zak Garcia is the company’s Chief Marketing Officer. He was the former CMO of Bulletproof Inc., maker of the well-known Bulletproof Coffee brand. Mr. Garcia is a marketing and leadership strategist who helped grow Bulletproof Coffee to over $250 million in revenue.

Delic Holdings Corp. (DELCF), closed Tuesday's trading session at $0.00365, up 8.9552%, on 13,250 volume. The average volume for the last 3 months is 13,250 and the stock's 52-week low/high is $0.0012/$0.0585.

Recent News

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.